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ABSTRACT 
Xuan Ou 
SIRT1 DEFICIENCY COMPROMISES MOUSE EMBRYONIC STEM CELL 
DIFFERENTIATION, AND EMBRYONIC AND ADULT HEMATOPOIESIS IN THE 
MOUSE 
 
SIRT1 (Sirtuin 1) is a founding member of a family of seven proteins and histone 
deacetylases. It is involved in cellular resistance to stress, metabolism, differentiation, 
aging, and tumor suppression. SIRT1
-/-
 mice demonstrate embryonic and postnatal 
development defects. We examined hematopoietic and endothelial cell differentiation of 
SIRT1
-/-
 mouse embryonic stem (mES) cells in vitro, and hematopoietic progenitors in 
SIRT1
+/+
, SIRT1
+/-
, and SIRT1
-/-
 mice. SIRT1
-/-
 ES cells exhibited markedly 
delayed/immature formation of blast colony-forming cells (BL-CFCs). When individual 
blast colonies were analyzed for hematopoietic and endothelial potential, replated SIRT1
-
/- 
BL-CFC possessed limited hematopoietic potential, whereas endothelial potential was 
essentially unaltered. The ability of SIRT1-/- ES cells to form primitive erythroid 
progenitors was not only delayed but greatly decreased.  Moreover, after differentiation 
of SIRT1
-/- 
mES cells, there were also significant decreases in granulocyte-macrophage 
(CFU-GM) and multipotential (CFU-GEMM) progenitor cells. Differentiation 
delay/defects were associated with delayed capacity
 
to switch off Oct4, Nanog and Fgf5, 
decreased β-H1 globin, β-major globin, and Scl gene expression and reduced activation 
of the Erk1/2 pathway upon SIRT1
-/-
 ES cell commitment. Reintroduction of WT SIRT1 
into SIRT1
-/-
 cells partially rescued the primitive erythroid progenitor formation of SIRT1
-
vi 
 
/-
 cells and the expression of hemoglobin genes, Hbb-bh1 and Hbb-b1, suggesting that the 
defect of hematopoietic commitment is due to deletion of SIRT1, and not to genetic 
drifting of SIRT1
-/-
 cells. To confirm the requirement for SIRT1 for normal development 
of hematopoietic progenitor cells, we assessed embryonic and adult hematopoiesis in 
SIRT1
+/+
, SIRT1
+/-
 and SIRT1
-/-
 mice. Yolk sacs from SIRT1 mutant embryos generated 
fewer primitive erythroid precursors compared to wild-type (WT) and heterozygous mice. 
Moreover, knockout of SIRT1 decreased primary bone marrow hematopoietic progenitor 
cells (HPCs) in 5 week and 12 month old mice, which was especially notable at lower 
(5%) O2 tension. In addition these progenitors survived less well in vitro under conditions 
of delayed growth factor addition. Taken together, these results demonstrate that SIRT1 
plays a role in ES cell hematopoietic differentiation and mouse hematopoiesis. 
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INTRODUCTION 
Embryonic Stem (ES) cells are derived from the inner cell mass (ICM) of mouse 
embryonic day (E) 3.5 blastocysts (Evans and Kaufman 1981; Martin 1981). ES cells 
have two unique characteristics that distinguish them from all other organ-specific cells. 
First, they can self-renew, that is they can be maintained and expanded as pure 
populations of undifferentiated cells for an extended period of time, possibly indefinitely, 
in culture. Second, they are pluripotent, possessing the capacity to generate every cell 
type in the body including germ cells. ES cells were initially established and maintained 
by co-culture with mouse embryonic feeder cells. Subsequently, in the late 1980‟s a 
factor in the feeder layer cells was identified that prevented differentiation and promoted 
stem cell self-renewal. Today this factor is known as Leukemia Inhibitory Factor (LIF), 
and allows ES cells to grow in the absence of feeder layer cells (Friel, van der Sar et al. 
2005). When moved from conditions that maintain them in an undifferentiated state and 
in suspension culture, ES cells grow into spheres termed embryoid bodies (EBs). Within 
this context, these cells differentiate into ectoderm, endoderm and mesoderm-derived 
tissues and give rise to many different somatic cell types (Figure 1). The ability to 
generate a wide spectrum of differentiated cell types from ES cells in culture offers a 
powerful approach for studying lineage induction and specification and a promising 
source of progenitors for cell replacement therapy.  
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Figure 1 
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Figure 1: In vitro differentiation of mouse ES cells.  
Undifferentiated mouse ES cells develop in vitro via three-dimensional aggregates EBs 
into differentiated cell types of all three primary germ layers. These three germ layers 
give rise to all organ-specific cell types of our body. Shown are a few examples: neurons, 
glial, epithelial cells, hematopoietic cells, cardiomyocytes, smooth muscle, pancreatic 
cells and hepatocytes. 
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Extracellular signaling that regulates self-renewal of mouse ES (mES) cells 
Several soluble factors have been identified that exert either positive or negative effects 
on ES cell self-renewal. As noted above, LIF, a member of interleukin 6 (IL-6) family is 
one of those factors and is known to strongly promote self-renewal in ES cells (Smith, 
Heath et al. 1988). LIF binding to leukemia inhibitory factor receptor (LIFR) on mES 
cells activates two major pathways, the Janus tyrosine associated kinase (JAK)-signal 
transducer activator of transcription 3 (STAT3) pathway and the Src homology 
phosphatase (SHP) 2-Extracellular Signal Regulated Kinase (ERK) pathway (Burdon, 
Chambers et al. 1999; Burdon, Stracey et al. 1999). LIF binds to LIF-Rβ and activates the 
JAKs which phosphorylate the SH-2 domain of their downstream target, STAT-3. Once 
STAT-3 is activated, it undergoes autophosphorylation and forms a STAT-3 homodimer. 
The STAT-3 dimer then translocates to the nucleus to activate a variety of downstream 
genes including myelocytomatosis oncogene (Myc, also known as c-Myc) and Krűppel-
like factor 4 (Klf-4), which positively control mES cell self-renewal (Niwa, Burdon et al. 
1998; Cartwright, McLean et al. 2005). 
Another pathway that is activated by LIF is the SHP2-ERK pathway via the gp130 
receptor. The LIF-gp130R activates the RAS/mitogen-activated protein kinase (MAPK) 
pathway. SHP2 associates with Gab1, which causes the activation of Ras, which induces 
the transactivation of MAPKs and ultimately ERK phosphorylation. This pathway leads 
to differentiation of murine ES cells (Burdon, Stracey et al. 1999; Burdon, Smith et al. 
2002) (Figure 2) (Kristensen, Kalisz et al. 2005). 
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Besides the LIF-STAT3 signaling pathway, recent studies have implicated BMP-Smad 
and Wnt-signaling pathways in the maintenance of ES cell pluripotency (Willert and 
Jones 2006; Wu and Hill 2009). 
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Figure 2 
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Figure 2: Regulation of self-renewal in mouse ES cells by Oct3/4, Nanog, BMP-
dependent SMAD, and LIF-dependent JAK/STAT3 signaling pathways.  
Self-renewal (proliferation) of undifferentiated mouse ES cells is regulated by Nanog, 
Oct-3/4, and tightly regulated interactions between LIF-dependent JAK/STAT3 
pathway(s) and BMP-dependent activation of Id target genes. A MEK-ERK signaling 
mechanism prevents ES cell self-renewal. Oct-3/4 and Nanog expression prevents 
differentiation into trophectoderm, primitive endoderm, and mesoderm cells. 
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Transcription factors controlling self-renewal of mES cells 
Extracellular signaling is transduced to the nucleus through transcription factors 
including STAT3 and MAPK. The factors listed below are part of the transcriptional 
network and play a central role in maintaining pluripotency. 
Oct3/4, also known as Pou5f1, consists of a POU domain as a DNA-binding domain, and 
two transactivation domains which lie on the N-terminus and the C terminus, respectively 
(Niwa, Masui et al. 2002). The expression of Oct3/4 is restricted in pluripotent cell 
lineages such as inner cell mass (ICM) and germ cells in vivo and undifferentiated ES 
cells in vitro, where it plays an indispensable role in maintaining pluripotency (Masui 
2010). In ES cells, continuous Oct3/4 function at appropriate levels is necessary to 
maintain pluripotency. A less than two fold decrease in expression causes differentiation 
into primitive endoderm and mesoderm, while loss of Oct3/4 induces the formation of 
trophectoderm concomitant with a loss of pluripotency (Niwa, Miyazaki et al. 2000). 
Oct3/4 regulates a broad range of target genes. From a developmental perspective, the 
main target is caudal type homeo box2 (Cdx2). Repression of Oct3/4 in ES cells results in 
differentiation into trophectoderm through upregulation of Cdx2; forced expression of 
that gene induces differentiation into trophectoderm (Niwa, Toyooka et al. 2005). Oct3/4 
has been known to activate downstream genes by binding to enhancers carrying the 
octamer-sox motif (Oct-Sox enhancer), for synergistic activation with the SRY-box 
containing gene 2 (Sox2). 
Sox2 expression is detected in pluripotent cell lineages and in the nervous system 
(Avilion, Nicolis et al. 2003). Sox2 consists of a DNA-binding HMG domain and a 
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transactivation domain that can be divided into three subdomains. The involvement of 
Sox2 in pluripotency maintenance was first suggested by the occupation of an enhancer 
consisting of Oct-Sox enhancer in the regulatory region of fibroblast growth factor (FGF) 
4. Oct-Sox enhancers are found in the regulatory region of most genes that are 
specifically expressed in pluripotent stem cells, such as Oct3/4, Sox2, Nanog, Utf1, and 
Fbx15 (Masui 2010). The primary role of Sox2 in ES cell self-renewal was found to be 
maintenance of Oct3/4 expression (Masui, Nakatake et al. 2007). 
Nanog is also a well-known homeobox transcription factor that is specially expressed in 
pluripotent cells (Mitsui, Tokuzawa et al. 2003). Nanog consists of three domains: a 
homeodomain similar to the NK-2 family, which acts as a DNA-binding domain, and the 
transactivation domains at the N-terminal and C-terminal, through which Nanog 
dimerizes to exert its full activity (Pan and Pei 2003; Wang, Levasseur et al. 2008). 
Nanog null embryos at E (embryonic day) 5.5 show disorganization of extraembryonic 
tissues with no discernible epiblast or extraembryonic ectoderm (Mitsui, Tokuzawa et al. 
2003; Okita and Yamanaka 2006). Nanog deficient blastocysts appear normal, but the 
ICM fails to give rise to epiblasts and only produces parietal endoderm-like cells when 
cultured in vitro. Similarly, mES cells lacking Nanog preferentially differentiate into 
extraembryonic endoderm lineages even in the presence of LIF, by repression of GATA-
binding protein 6 (Gata-6). In the blastocyst, Gata-6 is first expressed in some cells of the 
ICM, most of which differentiate into extra-embryonic endoderm cells. Interestingly, 
overexpression of Nanog allows mES cells to self-renew without LIF. Thus, Nanog 
blocks primitive endoderm differentiation and actively maintains pluripotency (Okita and 
Yamanaka 2006).  
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Klf4 was initially identified as a Klf family member expressed in the gut (Shields, 
Christy et al. 1996).  It contains C2H2-type zinc finger motifs. Klf4-null mice die within 
15 hours after birth due to a skin barrier defect caused by a perturbation in the 
differentiation of the epidermis (Segre, Bauer et al. 1999). A differentiation defect is also 
observed in the goblet cells of the colon in these knockout mice (Katz, Perreault et al. 
2002), indicating the indispensable function of Klf4 in the proper development of these 
organs. In ES cells, Klf4 participates in the activation of an Oct-Sox enhancer in 
cooperation with Oct3/4 and Sox2 (Nakatake, Fukui et al. 2006). Overexpression of Klf-4 
was found to prevent differentiation in embryoid bodies formed in suspension culture, 
suggesting that Klf4 contributes to ES self renewal (Li, McClintick et al. 2005). Klf4 in 
combination with Oct3/4, Sox2 and Myc can reprogram somatic cells into pluripotent 
stem cells (Nakagawa, Koyanagi et al. 2008). 
The ES cell property of self-renewal therefore depends on a stoichiometric balance 
among various signaling molecules. Other molecular markers potentially defining the 
molecular basis of stem cell identity or “stemness” include Rex-1 (Hosler, Rogers et al. 
1993), CD9, and stage specific embryonic antigen-1 (SSEA-1) and mES cells possess 
enzyme activities for alkaline phosphatase (ALP) (Wobus, Holzhausen et al. 1984) and 
telomerase (Armstrong, Lako et al. 2000). These markers are summarized in Table 1 
(Wobus and Boheler 2005). 
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Table 1: Markers and properties of mouse embryonic stem cells 
Marker mES cells
SSEA-1
SSEA-3/-4
TRA-1-60/81
TRA-2-54
GCTM-2
TG 343
TG 30
CD 9
CD 13/prominin
Alkaline phosphatase
Oct-4
Nanog
Sox-2
FGF4
LIF receptor
Telomerase activity
Regulation of self-renewal
Growth characteristics in vitro
EB formation
Teratoma formation in vitro 
+
-
--
-
-
?
?
+
+
+
+
+
+
+
+
+
Via gp 130R, MEF feeder layer
Tight, rounded, multiple layers
Simple and cystic EBs
+
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Table1: Markers and properties of mouse embryonic stem cells. 
 Identification of cell surface and molecular markers has proven critical to define the 
molecular basis of stem cell identity or “stemness”. It is now well established that 
undifferentiated mES cells express specific cell surface antigens SSEA-1 and possess 
enzyme activities for alkaline phosphatase. The fundamental characteristics of murine ES 
cells such as Oct-4 expression, telomerase activity, and the formation of teratomas 
containing derivatives of all three primary germ layers in immunodeficient mice are 
summarized in the table. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
In vitro differentiation potential of embryonic stem cells 
There is considerable interest in therapeutic applications of pluripotent cells derived from 
embryos. Much effort is being directed toward understanding the mechanisms for 
maintenance of the pluripotent state, as well as the pathways leading to lineage 
specification. During mouse embryogenesis, the primitive endoderm of the epiblast gives 
rise to three primary germ layers: the ectoderm, the mesoderm and the definitive 
endoderm. These germ layers interact to form all tissues and organs of the developing 
embryo. The complex interactions that control the transition of ectoderm to visceral and 
parietal endoderm in the postimplantation embryo, followed by the formation of 
mesoderm at the gastrulation stage (days 3 to 7 post coitum), are only beginning to be 
defined. The in vitro differentiation potential of mES cells has facilitated the examination 
of these processes (Wobus and Boheler 2005). 
In the absence of feeder layer cells and removal of LIF, ES cells differentiate into EBs. 
Within the EBs, it consists of derivatives of the three embryonic germ layers: mesoderm, 
endoderm and ectoderm (Keller 1995; Smith 2001), similar to those generated during 
mouse embryogenesis. Three general approaches, outlined in Figure 3, are used to initiate 
ES cell differentiation. In the first method, ES cells are allowed to aggregate and form 
three-dimensional colonies known as EBs (Doetschman, Eistetter et al. 1985; Keller 
2005). In the second method, ES cells are cultured directly on stromal cells, and 
differentiation takes place in contact with these cells. The most commonly used stromal 
cell line for such differentiation studies is OP9, originally isolated from the calvarium of 
CSF-1-deficient op/op mice (Niida, Kondo et al. 2005). The third protocol involves 
differentiating ES cells in a monolayer on extracellular matrix proteins. The three 
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differentiation methods have been used to generate a broad spectrum of cell types from 
ES cells. The first method is the one most used for differentiation of mES cells in vitro in 
our studies. Among three germ layers, mesoderm-derived lineages, including the 
hematopoietic, vascular, and cardiac, are the easiest to generate from ES cells and have 
been studied in considerable detail (Keller 2005). Of these, hematopoietic development is 
the best characterized (Keller 2005). Evidence from several different studies has 
demonstrated the developmental kinetics of various hematopoietic lineage precursors 
within EBs. The sequence of events leading to the onset of hematopoiesis within EBs is 
similar to that found within the mouse embryo. Thus, in vitro differentiation of ES cells 
to hematopoietic cells provides a unique opportunity to study mechanisms involved in the 
onset of hematopoietic development, and to characterize hematopoietic lineage-specific 
gene expression. 
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Figure 3 
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Figure 3: Three different protocols used for ES cell differentiation.  
The three methods have been used to generate a broad spectrum of cell types from ES 
cells (Keller 1995; Smith 2001). For lineages that have been studied in detail, the first 
two criteria outlined above have been met as efficient protocols for their differentiation 
have been established and the sequence of events leading to their development in culture 
was found to faithfully recapitulate those in the early embryo. The third aim has yet to be 
fulfilled for most populations. 
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Hematopoietic development in the mouse embryo 
Hematopoiesis in the early mouse embryo initiates at two independent sites, the yolk sac 
and an intraembryonic region known as the para-aortic splanchnopleura (P-Sp)/aorta-
gonad-mesonephros (AGM). Hematopoietic commitment is detected first in the yolk sac, 
where distinct blood islands appear, shortly following gastrulation (Moore and Metcalf 
1970). The yolk sac blood islands consist of two lineages, a population of erythroid cells 
surrounded by a layer of angioblasts that eventually form the developing vasculature. The 
parallel temporal development of these lineages in physical proximity provided the basis 
for the hypothesis that they arise from a common precursor, a cell called the 
hemangioblast (Keller, Lacaud et al. 1999; Kubo, Chen et al. 2005). The erythroid cells 
within these blood islands are known as embryonic or primitive erythrocytes (Keller, 
Lacaud et al. 1999). They are distinct from fetal and adult erythrocytes in that they are 
large, circulate in the bloodstream as nucleated cells for much of their life span, and 
contain an embryonic form of hemoglobin (Barker 1968; Brotherton, Chui et al. 1979). 
The primitive erythroid population represents the major mature hematopoietic component 
of the yolk sac and is restricted to the yolk sac between the primitive streak and 20 somite 
pair (sp) stage of development (Haar and Ackerman 1971; Palis, Robertson et al. 1999). 
One study suggests that these precursors are present in the yolk sac for a relatively short 
time, possibly no more than 48 hours, indicating that the entire primitive erythroid 
population could be produced in one rapid and synchronous wave of development (Wong, 
Chung et al. 1986; Keller, Lacaud et al. 1999). The other mature hematopoietic cells 
present in the yolk sac are macrophages as well as some megakaryocytes (Cline and 
Moore 1972; Xu, Matsuoka et al. 2001). The erythroid and megakaryocyte lineages are 
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tightly associated during development as a primitive bipotential megakaryocyte-erythroid 
progenitor has been detected in the mouse yolk sac (Klimchenko, Mori et al. 2009). 
Given the predominance of primitive erythropoiesis, this stage of hematopoietic 
development is known as primitive hematopoiesis. Primitive hematopoietic progenitors 
cannot fully recapitulate hematopoiesis in an adult undergoing transplantation. The 
second wave of hematopoiesis is termed definitive hematopoiesis (Palis, Robertson et al. 
1999). Although initiated in this extra-embryonic region, definitive hematopoiesis is most 
often associated with intra-embryonic sites such as the P-Sp, AGM (Godin, Dieterlen-
Lievre et al. 1995; Lacaud, Gore et al. 2002). Definitive hematopoiesis encompasses the 
development of all lineages other than primitive erythroid, and includes definitive 
erythroid, myeloid and lymphoid cells. Definitive erythroid cells are distinguished from 
primitive erythroid cells by the fact that they are small, enucleated and produce adult 
forms of globin (Barker 1968; Brotherton, Chui et al. 1979).  Definitive embryonic 
hematopoietic progenitors can restore hematopoiesis in an adult undergoing 
transplantation. 
In vitro differentiation of mES cells: a model for embryonic hematopoiesis 
Although yolk sac blood islands were identified as the earliest site of hematopoietic and 
endothelial development, attempts to identify, isolate and characterize the precursors 
representing these initial stages of lineage commitment, including the elusive 
hemangioblast, have been largely hampered by the inaccessibility of the early 
mammalian embryo. One promising alternative approach to study early hematopoietic 
development is the model system based on differentiation of ES cells in culture (Keller 
1995; Kyba, Perlingeiro et al. 2003). When induced to differentiate in culture, ES cells 
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form colonies known as EBs that contain three primary germ cell layers including 
mesoderm. Primitive erythroid precursors are the first hematopoietic population to 
develop from mesodermal progenitors and can be detected as early as day 4.0 upon 
differentiation of mES cells (Keller, Kennedy et al. 1993). Using the ESC/EB system, a 
precursor has been identified that is generated right after mesodermal precursors that 
responds to vascular endothelial growth factor (VEGF) and generates colonies consisting 
of blast cells. These VEGF-responsive blast cell colonies were shown to be able to 
generate endothelial, primitive erythroid and various definitive hematopoietic precursors. 
Shortly after the onset of primitive erythropoiesis, definitive precursors were detected in 
the following order: macrophage by day 4.0-4.5, definitive erythroid by day 4.5-5.0, and 
mast cell by day 8-9. Detailed analysis of the early stages of hematopoietic cell 
commitment has shown that both gene expression patterns and the kinetics of the lineage 
development within EBs are similar, if not identical, to those in the early yolk sac (Choi, 
Kennedy et al. 1998; Sroczynska, Lancrin et al. 2009). This unique advantage has been 
fully exploited to investigate the earliest stages of hematopoietic and endothelial cell 
commitment (Figure 4) (Keller, Lacaud et al. 1999; Keller 2005). 
Hemangioblast and hemogenic endothelium 
The ES differentiation model has also been exploited to test a long-standing hypothesis 
that the hematopoietic and endothelial lineages developed from a common progenitor, a 
cell known as the hemangioblast. Although this hypothesis was proposed many years ago, 
the identification, isolation and characterization of a precursor with these characteristics 
has eluded developmental biologists. Nevertheless, the concept of the hemangioblast has 
gained support from a variety of different experiments. First, analysis of early-stage, 
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carefully timed EBs led to identification of a progenitor known as the blast-colony-
forming cell (BL-CFC), that gives rise to blast-colonies consisting of hematopoietic and 
vascular progenitors in methylcellulose culture in the presence of VEGF (Kennedy, Firpo 
et al. 1997) (Figure 3). BL-CFCs represent a transient population that appears within EBs 
before the establishment of other hematopoietic lineages. The development potential of 
the BL-CFC strongly suggests that it represents the in vitro equivalent of the 
hemangioblast and, as such, the earliest stage of hematopoietic and endothelial 
commitment. Second, many studies have demonstrated that developing hematopoietic 
and endothelial cells express a number of genes in common, including CD34, Flk-1, Flt-1, 
Tie2, Scl/Tal-1, GATA-2 and PECAM-1(Baron 2003; Cumano and Godin 2007). Third, 
gene-targeting studies have shown a complete absence of hematopoietic and endothelial 
development in the yolk sac and P-Sp/AGM of embryos lacking a functional Flk-1 
receptor tyrosine kinase (Shalaby, Rossant et al. 1995; Shalaby, Ho et al. 1997; Keller, 
Lacaud et al. 1999) and a marked defect in the growth and development of both lineages 
in the yolk sac of embryos lacking transforming growth factor (TGF) β1 (Dickson, 
Martin et al. 1995; Keller, Lacaud et al. 1999). Fourth, studies on zebrafish have 
identified a mutation known as cloche that affects the development of hematopoietic 
lineages and endocardium in the embryo (Stainier, Weinstein et al. 1995). Fifth, 
Nishikawa et al. demonstrated the presence of precursors with hematopoietic and 
endothelial potential in Flk-1
+
 populations isolated from differentiating ES cells 
(Nishikawa, Nishikawa et al. 1998). 
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Figure 4 
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Figure 4: A comparison of BL-CFC development in EBs to hemangioblast 
development in the early mouse embryo.  
The EB and embryo are derived from an ES cell line in which the GFP cDNA has been 
targeted to the brachyury locus (Fehling et al. 2003; Huber et al. 2004). The presence of 
GFP in the EB and the primitive streak of the embryo is indicative of brachyury 
expression. 
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On the other hand, a newer theory proposes that hematopoietic stem cells form from a 
subset of early endothelial cells known as hemogenic endothelium (Figure 5). Nishikawa 
et al. isolated vascular endothelial (VE)-cadherin
+
 cells from either the yolk-sac or P-
Sp/AGM region of the embryo proper and demonstrated multilineage hematopoietic 
potential in these populations (Nishikawa, Nishikawa et al. 1998). As VE-cadherin is 
thought to be endothelial specific, these investigators concluded that these hematopoietic 
cells develop from a population of endothelial cells they referred to as hematogenic 
endothelium, a population that is presumably the functional equivalent of the 
hemangioblast. Conditional runx1 deletion in cells expressing TEK/Tie-2, a receptor for 
angiopoietin-1 expressed in endothelial cells, resulted in embryonic lethality similar to 
runx1-deficient embryos (Li, Chen et al. 2006; Yoshimoto, Porayette et al. 2008), 
supporting a role for hemogenic endothelium in putative HSC emergence. The 
relationship between hemangioblasts and hemogenic endothelium has not been resolved. 
Recently, several papers
 
have shed light on the potential relatedness and significance of 
these cell types. Lancrin et al. analyzed the sequence of cellular events required for the 
formation of mature blast colonies from cultured Flk-1
+
 cells by using time-lapse 
photography (Lancrin, Sroczynska et al. 2009; Yoshimoto and Yoder 2009). They found 
that these colonies formed in two stages. First, after 36-48 hours of „plating‟ Flk-1+ cells 
for growth in culture, the cells form tightly adherent clusters. Subsequently, round, non-
adherent cells appear which then proliferate to complete the formation of mature blast 
colonies. Among the adherent cell clusters at 48 hours, a transient cell population 
expressing various endothelial (but not mesoderm or BL-CFC) markers appears, 
displaying potential to form hematopoietic cells. From this population, both primitive and 
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definitive hematopoietic progenitors formed (Yoshimoto and Yoder 2009). The 
observations of Lancrin and colleagues (Lancrin, Sroczynska et al. 2009) suggest that 
hematopoietic progenitor cells arise from hemangioblasts through a hemogenic 
endothelial intermediate-the first linear pathway to resolve, at least in vitro, the 
relationship between hemangioblasts and hemogenic endothelium (Yoshimoto and Yoder 
2009).  
By continuous long-term single-cell observation of mouse mesodermal cells generating 
endothelial cell and blood colonies, Eilken et al. showed that it was possible to detect 
hemogenic endothelial cells giving rise to blood cells (Eilken, Nishikawa et al. 2009). 
The authors also directly isolated primary endothelial cells with hemogenic potential to 
form early mouse embryos. This demonstrates that hemogenic endothelial cells not only 
can be generated in vitro from ES cells but are also naturally present in mouse embryos 
(Yoshimoto and Yoder 2009). Furthermore, Chen et al. showed that most fetal liver and 
adult bone-marrow cells originate from the hemogenic endothelium (Chen, Yokomizo et 
al. 2009). Utilizing combinations of fluorescent reporter transgenes, confocal timelapse 
microscopy and flow cytometry, Bertrand et al. have directly imaged the birth of HSCs 
from the ventral wall of the dorsal aorta in the zebrafish embryo (Gerard, Bleyzac et al. 
2010). Their results, as well as previous studies in the avian (Jaffredo, Gautier et al. 
1998), amphibian (Ciau-Uitz, Walmsley et al. 2000), and mammalian embryo, discussed 
above suggest that the cellular mechanisms of HSC generation have been highly 
conserved across vertebrate evolution. The finding that HSC development requires 
transition through a hemogenic endothelial intermediate should aid efforts to instruct 
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HSC formation in vitro from pluripotent precursors, a necessity for therapies designed to 
replace adult blood cell lineages. 
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Figure 5 
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Figure 5: Model of hemangioblast differentiation towards hematopoiesis in the yolk 
sac.  
The first blood cell emerged from mesodermal progenitor cells. Mesodermal progenitor 
cells further differentiate into hemogenic endothelium, which is likely involved in 
primitive hematopoiesis and definitive hematopoiesis as well as vasculogenesis. There 
are two waves of hematopoiesis within the mouse. The first wave of hematopoiesis has 
been termed as primitive hematopoiesis given the predominance of primitive 
erythropoiesis in this stage. All lineages other than primitive erythroid, and early 
macrophage and megakaryocyte will be considered as belonging to the definitive 
hematopietic system.  
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Genes important in the development and regulation of the hemangioblast 
Although there is evidence that HSC can be generated from hemogenic endothelium, a 
question still remaining to be answered is whether HSCs emerge directly from hemogenic 
endothelial cells and whether the hemangioblast exists in vivo. As we wait for the answer, 
the following describes several genes important in the development and regulation of the 
hemangioblast. 
Flk-1 
Flk-1 is a receptor tyrosine kinase that binds VEGF. In primitive streak–stage embryos, 
Flk1 expression is first detectable in cells within and exiting
 
the primitive streak as well 
as the extraembryonic mesoderm (Yamaguchi, Dumont et al. 1993; Ema, Takahashi et al. 
2006). Subsequently, it can be detected in the endothelial cells lining
 
the blood islands of 
the extraembryonic yolk sac, the first
 
site of embryonic hematopoiesis, by E 7.5 (Lugus, 
Park et al. 2009). Flk-1 is an important marker required for functional hemangioblast 
formation and is required for blood and vessel formation. Mice deficient in the Flk-1 
receptor tyrosine kinase die in utero because of defective vascular and hematopietic 
development (Shalaby, Rossant et al. 1995). Both primitive and definitive blood cells are 
derived from Flk-1
+ 
mesoderm (Lugus, Park et al. 2009). Flk-1
-/- 
ES cells are nevertheless 
able to differentiate into hematopoietic and endothelial cells in vitro, but they give rise to 
a greatly reduced number of blast colonies. In addition, Flk-1
+
 but not Flk-1
– 
cells 
derived from ES cells generate T lymphocytes when
 
cocultured with lymphocyte-
depleted thymic lobes (de Pooter, Cho et al. 2003), and Flk-1
+ 
cells differentiated from 
ES cells in vitro are able to reconstitute
 
the hematopoietic systems in vivo in severe 
combined immunodeficient (SCID) mice (Miyagi, Takeno et al. 2002). Cell tracking 
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studies have indicated that the Flk-1 receptor is initially involved in migration of 
mesodermal precursor cells to the extraembryonic region of the embryo, the site of yolk 
sac development. These migrating precursors may be similar to the EB-derived BL-CFCs 
that have been shown to express Flk-1 and to grow in response to its ligand, VEGF (Irion, 
Clarke et al. 2010). 
Scl/Tal-1 
Scl (also known as Tal-1 for T-cell acute leukemia), a member of the helix-loop-helix 
family of transcription factors, functions at a slightly later developmental
 
stage than Flk-1. 
The yolk sacs of Scl
-/-
 embryos develop a primary vascular network but contain no 
primitive
 
or definitive hematopoietic cells, indicating a pivotal role for
 
Scl in 
hematopoietic commitment but not in the early stages of
 
vasculogenesis (Robb, Lyons et 
al. 1995). Although not essential for establishment of
 
the endothelial lineage, Scl does 
appear to be required for remodeling
 
and maturation of the vascular system (Visvader, 
Fujiwara et al. 1998). In vitro differentiation
 
studies with Scl
-/- 
ES cells show a complete 
block in primitive and definitive
 
hematopoietic potential, confirming the developmental 
defect observed
 
in vivo (Robertson, Kennedy et al. 2000). Further analysis of the Scl
-/-
 
EBs reveals a defect as early as the BL-CFC because mutant
 
ES cells were unable to 
generate blast cell colonies.
 
Scl
-/-
 ES cells were, however, able to generate precursors that 
give
 
rise to transitional colonies that represent a stage of development
 
slightly earlier than 
the blast cell colony (Robertson, Kennedy et al. 2000). These colonies, named transitional 
colonies, are also generated by WT ES cells and are easily distinguished by 
morphological criteria from blast cell colonies and secondary EBs that develop in these 
replated colonies (Lacaud, Robertson et al. 2001). Functional studies support this 
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interpretation and demonstrate that BL-CFC, endothelial precursors and primitive and 
definitive hematopoietic precursors do develop into transitional colonies. Transitional 
colonies generated from Scl
-/-
 EBs have endothelial precursors, but no hematopoietic 
potential (Lacaud, Robertson et al. 2001). Recently, Lancrin et al. demonstrated that the 
transcription factor Scl is indispensable for the establishment of hemogenic endothelium 
population whereas the core binding factor Runx1 (also known as AML1) is critical for 
generation of definitive hematopoietic cells from hemogenic endothelium (Lancrin, 
Sroczynska et al. 2009). 
Runx1 
The AML1 gene (recently renamed Runx1) encoding the DNA-binding subunit of a 
transcription factor of the core binding
 
factor (CBF) family, is required for establishment 
of
 
definitive but not primitive hematopoiesis at the hemangioblast stage of development 
(Lacaud, Gore et al. 2002). Runx1
-/-
 embryos develop normal blood islands and progress 
through the
 
yolk sac phase of hematopoiesis, but die between E11 and E12.5 (Wang, 
Stacy et al. 1996).
 
Before death, the liver rudiment contains primitive nucleated
 
erythrocytes but lacks all definitive erythroid, myeloid, and
 
megakaryocytic cells, 
indicating a complete block in development
 
of the definitive hematopoietic program. 
Analysis of Runx1
-/-
 EBs revealed a similar block in definitive hematopoietic potential 
(Lacaud, Gore et al. 2002).
 
In addition to hematopoietic abnormalities, Runx1-deficient
 
animals show extensive central nervous system hemorrhage and necrosis,
 
suggesting an 
additional vascular
 
defect (Wang, Stacy et al. 1996). Recently, two papers showed that 
Runx1 functions during the transition from „hemogenic endothelium‟ to HSCs and Runx1 
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function is essential in endothelial cells for hemogenic progenitor and HSC formation 
from the vasculature (Chen, Yokomizo et al. 2009; Lancrin, Sroczynska et al. 2009). 
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Background on Sirtuins 
Mammalian sirtuins 
Sirtuins in mammals were named based on their homology to the Saccaromyces 
cerevisiae gene silencing information regulator 2 (Sir2).  The sirtuins consist of seven 
members, designated  silent information regulator homologue (SIRT) 1 through SIRT7 
(Blander and Guarente 2004). They share significant sequence homology and contain a 
nicotinamide adenine dinucleotide (NAD
+
)-dependent catalytic core domain, which may 
act as either a mono-ADP-ribosyl transferase (ART), a NAD
+
-dependent deacetylase 
(DAC), or both (North, Marshall et al. 2003). The N-and/or C-terminal sequences are of 
variable lengths between different sirtuins. Each sirtuin also has a different localization 
and function. SIRT1, SIRT6 and SIRT7 are predominately in the nucleus. SIRT2 is 
predominately cytoplasmic. SIRT3, 4 and 5 are mainly mitochondrial proteins. (Cohen, 
Miller et al. 2004; Hallows, Lee et al. 2006). Although SIRT1 was initially known as a 
nuclear protein, it has recently been found to shuttle between the nucleus and the 
cytoplasm to manifest its function (Tanno, Sakamoto et al. 2007; Iwahara, Hisahara et al. 
2009). Of the sirtuin family members, SIRT1 is the most well studied, and has been 
shown to participate in a number of processes including metabolism, cell survival, 
chromatin remodeling and differentiation (Anastasiou and Krek 2006; Mantel, Wang et al. 
2008; Wang, Sengupta et al. 2008; Finkel, Deng et al. 2009; Haigis and Sinclair 2010). 
Consistent with its diverse biological functions, SIRT1 regulates several transcription 
factors including FOXO factors, PGC-1, p53 and Ku70 (Blander and Guarente 2004; 
Rodgers, Lerin et al. 2005). Other Sirtuin family members (SIRT2-SIRT7) also play 
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important roles in cell cycle control, DNA repair, and rDNA transcription (Table 2) (Frye 
2000; Haigis and Sinclair 2010).  
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Adapted from T Finkel et al. Nature 460, 587-591 (2009) doi:10.1038/nature08197 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Summary of mammalian sirtuins 
Sirtuin
SIRT1
SIRT2
SIRT3
SIRT4
SIRT5
SIRT6
SIRT7
Locations
Nucleus
Cytosol
Mitochondria
Mitochondria
Mitochondria
Nucleus
Nucleus
Interactions
FOXO, PGC-1α,  
NF-kβ, Ku70, etc
Tubulin, H4, FOXO
AceCS2, GDH
GDH, IDE, ANT
CPS1
Histion3, NF-kβ
Pol I
Biology
Metabolism, stress
Cell cycle
Thermogenesis
ATP production
Insulin secretion
Urea cycle
Base excision 
repair, metabolism
rDNA transcription
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Table 2: Cellular distribution, target proteins and functions of mammalian sirtuins 
The mammalian Sir2 gene family is comprised of seven members. Each is defined by a 
conserved core domain, and some contain additional N- or C-terminal sequences. SIRT1 
interacts with, deacetylases a growing number of proteins, and plays key function in, but 
not limited to, metabolism, stress and aging. Other family members and their functions 
are also listed in above table. 
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SIRT1 Function in Aging 
The initial identification of SIRT1 (yeast SIR2) as a lifespan regulator was in a genetic 
screen to isolate long-living mutants in yeast Saccharomyces cerevisiae (Kennedy, 
Austriaco et al. 1995). Kennedy et al. found that a SIR4 mutant extended yeast lifespan 
by measuring the number of cell divisions undergone by the yeast mother cell (Kennedy, 
Austriaco et al. 1995). Later, it was shown that deletion of either SIR3 or SIR4 results in 
a moderate shortening in lifespan, and SIRT1 (yeast SIR2) mutations severely reduce 
lifespan (Kaeberlein, McVey et al. 1999). The life span shortening by SIR2 mutants was 
due to an increase in homologous recombination at the rDNA loci, which results in the 
formation of an extrachromosomal rDNA circle (ERC) in the nucleolus. Accumulation of 
ERCs lead to cell cycle arrest, cellular senescence, and aging (Hutchin, Heath et al. 1997). 
SIR2 represses recombination at the rDNA locus and prevents generation of ERCs, thus 
slowing down the aging process (Kaeberlein, McVey et al. 1999). 
Regulation of lifespan by SIRT1 has been shown to be conserved in a wide range of 
organisms (Tissenbaum and Guarente 2001; Astrom, Cline et al. 2003; Rogina and 
Helfand 2004; Hashimoto, Horikawa et al. 2010). Tissenbaum & Guarente reported over-
expression of Sir2.1, the worm SIRT1 homolog, significantly extended life span for 
Caenorhabditis elegans (Tissenbaum and Guarente 2001). In Caenorhabditis elegans, 
mutations that reduce the activity of an insulin-like receptor daf-2 or a 
phosphatidylinositol-3-OH kinase age-1 favour entry into the dauer state during larval 
development and extend lifespan in adults. Downregulation of this pathway activates a 
forkhead transcription factor daf-16, which may regulate targets that promote dauer 
formation in larvae and stress resistance and longevity in adults. Recently, Hashimoto T 
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et al. have shown that nicotinamide adenine dinucleotide extends the lifespan of 
Caenorhabditis elegans mediated by sir-2.1 and daf-16 (Hashimoto, Horikawa et al. 
2010). Similarly, in the fly, drosophila melanogaster, an extra copy of the dSir2 gene 
extends the lifespan of flies by up to 29% through a pathway related to caloric restriction 
(CR) (Rogina and Helfand 2004). Astrom et al. found that a dSir2 knockout fly has wild 
type viability, developmental rate, and sex ratio. However, they showed that dSir2 
knockout results in shortening of fly life span (Astrom, Cline et al. 2003). 
Involvement of mammalian sirtuins in determining organismal life has been extensively 
investigated. Increasing evidence has suggested that in the complex mammalian system 
sirtuins may affect aging by regulating multiple independent processes such as glucose 
homeostasis, insulin secretion, and stress resistance (Luo, Nikolaev et al. 2001; Vaziri, 
Dessain et al. 2001; Brunet, Sweeney et al. 2004; Cohen, Miller et al. 2004; Motta, 
Divecha et al. 2004; Picard, Kurtev et al. 2004; Moynihan, Grimm et al. 2005; Rodgers, 
Lerin et al. 2005; Bordone, Motta et al. 2006; Nayagam, Wang et al. 2006). Some reports 
have attempted to look at the direct effects of SIRT1 in mammalian tissues and organ 
longevity (Alcendor, Gao et al. 2007). Using transgenic mice with heart-specific 
overexpression of SIRT1, it was shown that low to moderate overexpression of SIRT1 
attenuates the age-dependent increase in cardiac hypertrophy, apoptosis/fibrosis, cardiac 
dysfunction, and expression of senescence markers (Alcendor, Gao et al. 2007), 
suggesting that SIRT1 could retard aging and confer stress resistance to the heart at low 
to moderate doses (Alcendor, Gao et al. 2007). Numerous studies have shown that caloric 
restriction promotes life span extension by up to 50% in a wide range of organisms, 
including yeast, worms, flies, and mice indicating the role of adipose tissue in life span. It 
38 
 
has been documented that decreased adiposity in fat-specific insulin receptor knockout 
mice leads to increased lifespan. Interestingly, SIRT1 plays a critical role in fat storage 
and adipogenesis in mammals, thereby linking adipose regulation of longevity to SIRT1 
(Ghosh, Spencer et al. 2007). Calorie restriction (CR) refers to a dietary regime, low in 
calories without nutrition. SIRT1 null mice have been used to provide evidence that 
SIRT1 mediates aspects of CR. SIRT1 overexpressing transgenic mice displayed some 
phenotypes similar to mice on a calorie-restricted diet such as leaner body mass, higher 
metabolic activity, reduced blood cholesterol, adipokines, insulin and fasted glucose 
levels and higher glucose tolerance than littermate controls. Furthermore, transgenic mice 
performed better on a rotating rod challenge and also showed a delay in reproduction 
(Bordone, Cohen et al. 2007). Recently, life span of SIRT1 null mice has been measured. 
SIRT1 null mice have a shorter life span than do their WT littermates, and CR does not 
increase the life span of these animals, providing some direct evidence that SIRT1 
regulates aging by CR in mammals. However, firm conclusions are complicated by the 
fact that SIRT1 null mice that survive to adulthood die prematurely and have 
developmental defects. Life span studies that use SIRT1 tissue-specific knockout mice 
may ascertain which tissue drives the developmental defects (Haigis and Sinclair 2010).  
SIRT1 function in metabolic regulation 
Glucose metabolism is a major regulator of cellular energy state and a critical component 
of the physiology of CR. Organisms with CR mediated longevity show increased insulin 
sensitivity and corresponding reduction in glucose concentration and insulin levels.  
SIRT1 has been shown to regulate glucose homeostasis in two tissues (Ghosh, Spencer et 
al. 2007). One is in the pancreas, associated with a physiological role of SIRT1 in insulin 
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secretion (Moynihan, Grimm et al. 2005; Bordone, Motta et al. 2006). Another is SIRT1 
function in glucose metabolism in the liver (Frescas, Valenti et al. 2005). 
Two independent studies have shown a role for SIRT1 in regulation of insulin secretion 
in the pancreas. Pancreatic β-cells play a central role in maintaining glucose homeostasis 
in mammals by secreting insulin in response to elevated blood glucose levels. β-cells 
have a highly coordinated mechanism that senses glucose and transduces its signal to 
insulin secretion. In the murine pancreas, SIRT1 is preferentially expressed in -cells 
(Moynihan, Grimm et al. 2005). Moyhihan et al. have shown that specific overexpression 
of SIRT1 in β-cells enhanced glucose-stimulated insulin secretion in transgenic mice and 
hence improved their glucose tolerance (Moynihan, Grimm et al. 2005). Conversely, 
knockdown of SIRT1 in β-cell lines compromised insulin secretion. SIRT1 achieved this 
effect at least partially by repressing transcription of the uncoupling protein (UCP)-2 by 
directly binding to the UCP-2 promoter (Moynihan, Grimm et al. 2005). Uncoupling 
protein-2 is a mitochondrial inner-membrane protein that uncouples oxygen consumption 
during respiration from ATP production by allowing proton leakage down an 
electrochemical gradient from cytoplasm to mitochondria. Hence, decreased UCP-2 
expression mediated by SIRT1 leads to better coupling of mitochondrial respiration and 
ATP synthesis, which enhances ATP production and thereby sensitizes β-cells to blood 
glucose level. This is reminiscent of the phenotype of UCP-2
-/-
 mice, which exhibited 
higher ATP levels in pancreatic islets and increased insulin secretion in response to 
glucose stimulation, whereas over-expression of UCP-2 in cultured β-cell lines reduces 
ATP levels and glucose-stimulated insulin secretion (Zhang, Baffy et al. 2001). Bordone 
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et al. have shown that SIRT1
-/-
 mice have low level of blood insulin and UCP-2 levels are 
increased in SIRT1
-/-
 mice and SIRT1-knockdown cells (Bordone, Motta et al. 2006). 
Liver is another organ that is important in maintaining glucose and lipid homeostasis. 
SIRT1 has been shown to regulate gluconeogenesis in liver by two mechanisms, one 
involving the FOXO1 protein and the other through PGC1-α.  SIRT1 deacetylases the 
transcription factor FOXO1. Subsequently, the enhanced expression of FOXO-1 target 
genes leads to activation of gluconeogenesis and increased glucose release from 
hepatocytes (Frescas, Valenti et al. 2005). In addition, SIRT1 also interacts with and 
deacetylases transcriptional co-activator PGC1-α in a ternary complex with hepatocyte 
nuclear factor (HNF-4) to induce gluconeogenesis following fasting (Rodgers, Lerin et al. 
2005). 
Overall, the above evidence suggests an impact of SIRT1 function on body glucose 
homeostasis through its role in insulin secretion in the pancreas and gluconeogenesis in 
the liver. Thus the activity of SIRT1 may be a relevant therapeutic target for diabetes. 
SIRT1 function in lipid metabolism 
Another tissue involved in metabolic regulation is adipose tissue, a major site of 
triglyceride (TG) storage, which is an important energy source when glucose is scarce in 
the blood. During fasting or starvation, adipose TG is mobilized to produce free fatty 
acids (FFA), which can be used by other tissues for energy production (Flier 2004). 
Several studies have been shown that SIRT1 may be one of the potential molecules 
linking adipose tissue, the effect of food restriction and longevity (Bordone and Guarente 
2005; Kloting and Bluher 2005; Fischer-Posovszky, Kukulus et al. 2010). The nuclear 
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receptor PPAR (peroxisome proliferation-activated receptor-) is a ligand-activated 
transcription factor which functions as the master regulator of adipogenesis and fat 
storage in white adipose tissues (WAT). SIRT1 reduces adipogenesis and TG 
accumulation in the lipid droplets of adipocytes by repressing PPAR through the 
transcriptional co-repressor NCoR and silencing mediator for retinoid and thyroid 
hormone receptor (SMRT) (Picard, Kurtev et al. 2004). Consistently, SIRT1
+/-
 mice have 
low levels of blood FFAs upon fasting or β-adrenergic stimulation and nicotinamide 
(NAM), a SIRT1 inhibitor, significantly increases fat mass in these mice. Conversely, 
resveratrol (RSV), a SIRT1 activator, potentially induces mitochondrial activity, through 
activating PGC1-α by facilitating SIRT1-mediated deacetylation. Furthermore, mice 
treated with RSV demonstrate a smaller amount of WAT, a reduction in fat storage and 
smaller adipocytes. In addition, mobilization of FFAs from WAT in response to fasting is 
impaired in SIRT1
-/-
 mice (Howitz, Bitterman et al. 2003; Picard, Kurtev et al. 2004). 
Another molecular mechanism of SIRT1 in regulating lipid metabolism is demonstrated 
by Hallows WC et al. (Hallows, Lee et al. 2006). They showed that mammalian Acetyl-
CoA synthetases (AceCSs) are regulated by reversible acetylation and SIRT1 activates 
the mammalian acetyl CoA synthetase 1 (AceCs-1) via deacetylation. AceCSs catalyzes 
the synthesis of AceCoA, a key molecule in mitochondrial oxidation and lipid synthesis. 
Regulation by SIRT1 of AceCS-1 suggests that SIRT1 possibly modulates lipid 
metabolism by regulating intracellular acetyl-CoA levels (Hallows, Lee et al. 2006; 
Lomb, Laurent et al. 2010) 
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SIRT1 and cancer 
Many cancers are recognized as age associated diseases because of their prevalence with 
increasing age. It has been debated whether SIRT1 is a potential oncogene or a potential 
tumor suppressor. SIRT1 plays a dual role in cell survival and cell death and can be 
modulated in different directions by a variety of different stimuli. On the one hand, 
SIRT1 deacetylates and suppresses the tumor suppressor p53 (Luo, Nikolaev et al. 2001; 
Chua, Mostoslavsky et al. 2005). Deacetylation of lysine 382 on p53 by SIRT1 reduces 
p53 transactivation, allowing cells to bypass p53-mediated apoptosis. Increased SIRT1 
expression in human fibroblasts has been shown to promote cellular proliferation, 
increase growth rate, reduce cellular senescence, and increase the cellular life span of 
human embryonic lung fibroblasts 2Bs, while reducing expression of p16
INK4A
, and 
promoting phosphorylation of Rb (Haigis and Sinclair 2010). Overexpression of SIRT1 
has also been shown to repress expression or activity of tumor-suppressor and DNA-
repair genes, including FOXO1/2/4, WRN, Rb, p73, MLH1, and NBS1. These data, 
combined with other studies showing that SIRT1 can suppress apoptosis, imply that 
SIRT1 might be oncogenic (Haigis and Sinclair 2010).  
Two tumor suppressors have been identified as negative regulators of SIRT1. The tumor 
suppressor HIC1 (hyper-methylated in cancer-1) directly represses SIRT1 to modulate 
the p53-dependent DNA-damage response (Chen, Wang et al. 2005). Importantly, the 
authors find that the HIC1 promoter undergoes hypermethylation during aging, which 
may lead to upregulation of SIRT1 during aging and therefore, susceptibility to cancer. 
Another tumor suppressor that negatively regulates SIRT1 is DBC1 (deleted in breast 
cancer 1) (Kim, Chen et al. 2008; Zhao, Kruse et al. 2008). The authors showed that 
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DBC1 acts as a inhibitor of SIRT1 in human cells. DBC1-mediated repression of SIRT1 
leads to increasing levels of p53 acetylation and upregulation of p53-mediated function. 
In contrast, depletion of endogenous DBC1 by RNA interference (RNAi) stimulates 
SIRT1-mediated deacetylation of p53 and inhibits p53-dependent apoptosis. Notably, 
these effects can be reversed in cells by concomitant knockdown of endogenous SIRT1. 
This indicates that DBC1 may promote breast cancer in part by activating SIRT1, thereby 
downregulating p53 and/or other tumor-suppressor pathways. 
On the other hand, recent work indicates that SIRT1 serves as a tumor suppressor. 
Firestein et al. demonstrated that overexpression of SIRT1 in APC
min/+
 mice reduces 
colon cancer formation (Firestein, Blander et al. 2008). Min mice are heterozygous for a 
germ-line mutation in Apc, the mouse homolog of the human APC gene. Min mice on the 
C57BL/6J (B6) background develop numerous adenomatous polyps throughout the small 
and large intestine (Moser, Pitot et al. 1990). They showed that the reduction in tumor 
development is caused by the ability of SIRT1 to deacetylate β-catenin and promote 
cytoplasmic localization of the nuclear-localized oncogenic form of β-catenin. Their 
further analysis also uncovered a significant inverse correlation between the presence of 
nuclear SIRT1 and the oncogenic form of β-catenin in 81 human colon tumor specimens 
analyzed. Ectopic overexpression of SIRT1 also greatly reduces cell proliferation in a 
human colon cancer cell line whose growth is driven by active β-catenin (Firestein, 
Blander et al. 2008; Luo and Altieri 2008). 
Analyzing published database for SIRT1 expression, Wang et al. found that SIRT1 
expression is much lower in the BRCA1-associated breast cancer than BRCA1-wildtype 
breast cancer in human (Wang, Zheng et al. 2008). They further showed that BRCA1 
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binds to the SIRT1 promoter and positively regulates SIRT1 gene expression at both the 
mRNA and protein level, and that BRCA1 deficiency causes reduced SIRT1 levels, 
which may be responsible for the malignant transformation of BRCA1 mutant cells. 
Consistently, restoration of SIRT1 levels in BRCA1 mutant cancer cells inhibited 
proliferation of these cells in vitro and tumor formation in vivo when the cells were 
implanted into nude mice. The underlying molecular mechanism is that SIRT1 negatively 
regulates transcription of survivin, which encodes an anti-apoptotic protein, by 
deacetylating H3K9 within the promoter of survivin (Wang, Zheng et al. 2008; Deng 
2009). Together, these data suggest that SIRT1 mediates BRCA1 signaling and inhibits 
tumor growth through repressing transcription of oncogenes or activity of oncoproteins. 
Wang et al. have shown that SIRT1
+/-
; p53
+/-
 mice develop spontaneous tumors in 
multiple organs from about 5 months of age, and tumor incidence reaches about 76% by 
20 months of age, while only 2 out of 21 SIRT1
+/-
 mice and 3 out of 22 p53
+/-
 mice 
developed tumors during the same period of time. Chromosome spreads and spectral 
karyotyping analysis of primary tumors revealed extensive aneuploidy and chromosomal 
aberrations, notably translocations, chromosome breaks, deletions, end fusions, and 
dicentric chromosomes. These results suggest that severe genetic instability could be one 
of the causes for spontaneous tumorigenesis in SIRT1 and p53 double-heterozygous 
animals. Interestingly, most tumors developed in the SIRT1
+/-
; p53
+/-
 mice lost the 
remaining WT allele of p53, yet retained a functional wild-type SIRT1 allele. 
Accordingly, administration of resveratrol to these mice significantly reduced tumor 
formation (Wang, Sengupta et al. 2008; Deng 2009). These data demonstrate that SIRT1 
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plays a critical role in maintaining genome integrity and acts as SIRT1 serves as a 
haploid tumor suppressor gene in mice.  
The work summarized above represents a strong body of evidence supporting a role for 
SIRT1 in cancer development. Yet, the controversy over whether SIRT1 serves as a 
tumor promoter or a tumor suppressor has not been resolved and discussion will likely 
continue. 
SIRT1 function in vascular endothelial homeostasis 
Recent studies point to SIRT1 as a key regulator of vascular endothelial homeostasis 
controlling angiogenesis, vascular tone and endothelial dysfunction. Using a three-
dimensional assay of sprouting angiogenesis assay combined with RNA interference to 
specifically knock down SIRT1 as a model system, Potente et al. (Potente, Ghaeni et al. 
2007) showed that SIRT1 is a critical regulator of sprouting angiogenesis during vascular 
growth. Furthermore, the authors analyzed SIRT1 mutant mice and found that those mice 
were impaired in their ability to form new vessels in response to angiogenic signals such 
as ischemic stress (Potente, Ghaeni et al. 2007).  A clue to the mechanism of how SIRT1 
modulates endothelial angiogenic function came from time-lapse analysis of segmental 
vessel formation in transgenic zebrafish embryos with fluorescently labeled endothelial 
cells in which segmental arteries emanate from the dorsal aorta to form the dorsal 
longitudinal anastomosing vessel. Comparing the highly organized process of blood 
vessel formation in control embryos, SIRT1-deficient zebrafish were characterized by 
vascular patterning defects and hemorrhages due to dysregulated endothelial sprouting 
and vessel navigation (Potente, Ghaeni et al. 2007; Potente and Dimmeler 2008; Guarani 
and Potente 2010). By means of gain- and loss-of-function approaches, they 
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demonstrated that SIRT1 represses FOXO-1 dependent transcriptional activity in 
endothelial cells, and, thus, point to this transcription factor as an effector in the SIRT1-
dependent angiogenic signaling pathway (Potente and Dimmeler 2008; Chen, Peng et al. 
2010).  
In addition to its function as a regulator of angiogenesis, SIRT1 may be involved in 
endothelial homeostasis by regulating the endothelial nitric oxide synthase (eNOS). 
Mattagajasingh et al. demonstrated that SIRT1 promotes endothelium-dependent 
vasodilation by targeting eNOS for deacetylation, leading to enhanced nitric oxide 
production (Mattagajasingh, Kim et al. 2007). Resveratrol, a polyphenolic activator of 
SIRT1, increases the expression of eNOS and the combination of resveratrol with the 
HMG-CoA reductase (statins) increased activation of eNOS resulting in increased 
functional recovery in a model of acute myocardial infarction (Wallerath, Li et al. 2005; 
Penumathsa, Thirunavukkarasu et al. 2007; Rush, Quadrilatero et al. 2007). A recent 
study by Chen and colleagues further explain the mechanisms underlying post-
transcriptional activation of eNOS by SIRT1 (Chen, Peng et al. 2010). SIRT1 
deacetylation of eNOD requires AMPK phosphorylation of eNOS. Atheroprotective flow, 
via AMPK and SIRT1, increases NO bioavailability in endothelium (Chen, Peng et al. 
2010). Taken together, these findings suggest SIRT1 as a key regulator of tissue 
homeostasis by defining the vascular endothelium as an important target tissue for direct 
or indirect actions of SIRT1. 
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SIRT1 function in development 
SIRT1 is expressed at high levels in mouse embryos with highest mRNA expression is 
E4.5 embryos. Although expression is down-regulated during subsequent embryogenesis, 
high level expression remains detectable at E18.5 (Sakamoto, Miura et al. 2004). Many 
lines of evidence suggest a role of SIRT1 in development. McBurney et al. showed that 
the protein SIRT1 is important for embryogenesis and gemetogenesis (McBurney, Yang 
et al. 2003). SIRT1 mutant mice carrying a truncation mutation through targeted 
replacement of exons 5 and 6 with a hygromycin gene demonstrate 50% mortality at an 
early postnatal stage (McBurney, Yang et al. 2003). These mice showed developmental 
defects such as markedly smaller size as compared to their littermates, slower 
development, defects in eye morphogenesis and cardiac septation. Furthermore, the mice 
that survive to adulthood were sterile in both sexes, with males having lower sperm count 
and females failing to ovulate, potentially due to hormonal inefficiency (McBurney, 
Yang et al. 2003). Cheng et al have demonstrated that up to 90% of SIRT1 mutant mice 
carrying a deletion of exon 4 die perinatally and those mice exhibit developmental 
defects of retina and heart, with the remaining 10% of these mutants still surviving at 
weaning (Cheng, Mostoslavsky et al. 2003; McBurney, Yang et al. 2003; Coussens, 
Maresh et al. 2008). A recent study (Wang, Sengupta et al. 2008) showed that a majority 
of SIRT1
-/- 
mice died at E9.5-E14.5; whereas about 1% of the mutants on the 
129SvEv/FVB background and 9.3% on the 129SvEv/FVB/Black Swiss background 
survived to adulthood (Wang, Sengupta et al. 2008). In addition, studies showed that 
SIRT1 influences growth-factor responses and maintenance of embryonic and 
hematopoietic stem cells (Han, Song et al. 2008; Mantel and Broxmeyer 2008; Narala, 
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Allsopp et al. 2008). Taken together, these studies suggest that SIRT1 is important in 
embryonic development. Thus, functions of SIRT1 are worth investigating to better 
understand mammalian embryogenesis. 
SIRT1 activators and inhibitors 
The apparent role of SIRT1 and other sirtuin family members in a variety of 
physiological processes and diseases have prompted searches for compounds that can 
activate or inhibit SIRT1, since such compounds may potentially provide clinical 
treatment and therapies. In 2003, the first such molecule, Resveratrol, a compound 
produced by plants in response to stress was discovered by Howitz et al. and they found 
that this molecule extend Saccharomyces cerevisiae lifespan (Howitz, Bitterman et al. 
2003). Since then, many polyphenol activators of SIRT1 have been discovered such as 
Quercetin, Buetin, SRT1720, Pyrroloquinoxaline and Oxazolopyridine. These 
compounds are collectively called the Sirtuin Activating Compounds or STACs (Ghosh 
2008).  
Resveratrol, the activator that has been investigated most extensively, is a polyphenolic 
compound found naturally in grape skin and a variety of plant products such as fruits and 
nuts, and was initially reported to increase the catalytic activity of SIRT1 in vitro. 
Resveratrol has also shown effects mimicking SIRT1 activation such as promoting cell 
survival by deacetylation of p53, inhibiting adipocyte differentiation by PPAR-γ, and 
sensitizing cells to TNF-α induced apoptosis by NF-κB deacetylation (Picard, Kurtev et 
al. 2004; Yeung, Hoberg et al. 2004; Parker, Arango et al. 2005). Subsequently, it has 
been reported to modulate a variety of processes in mammals in a SIRT1-dependent 
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manner such as neuroprotection, differentiation, tumor suppression and inflammation 
(Baur, Pearson et al. 2006; Labinskyy, Csiszar et al. 2006; Anekonda and Adamus 2008; 
Baur 2010). Consistently, resveratrol effects a number of diseases in mammals including 
cancer, heart diseases, brain damage, hearing loss and injuries to tissues (Baur and 
Sinclair 2006). Thus, resveratrol may provide us a promising therapy and future research 
will probably tackle key medical issues like stroke, heart disease, and so on based on 
their findings concerning resveratrol's therapeutic properties.  
Biological functions of SIRT1 have triggered interest in the development of not only 
SIRT1 activators but also inhibitors. Sir2 enzymes catalyze NAD
+
-dependent 
protein/histone deacetylation, where the acetyl group from the lysine epsilon-amino 
group is transferred to the ADP-ribose moiety of NAD
+
, producing nicotinamide and the 
novel metabolite O-acetyl-ADP-ribose. Bitterman et al. showed that physiological 
concentrations of nicotinamide inhibit both Sir2 and SIRT1 in vitro (Bitterman, Anderson 
et al. 2002). Several other chemical inhibitors of SIRT1 have more recently been 
identified including Sirtinol, EX-527, Cambinol and Tenovin (Napper, Hixon et al. 2005; 
Haigis and Sinclair 2010). Studies on inhibitors and activators of SIRT1 will likely be 
ongoing in order to determine if it is possible to safety target SIRT1 and other sirtuin 
family members to treat “SIRT-associated” diseases. 
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HYPOTHESIS 
We hypothesized that SIRT1 plays a role in embryonic and adult hematopoiesis in the 
mouse. 
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AIMS 
AIM 1: Determine the role of SIRT1 in self-renewal and differentiation of mouse 
embryonic stem (mES) cells using the in vitro model of differentiation of ES cells into 
embryoid body (EB) cells, and explore the molecular mechanisms associated with the 
phenotype. 
AIM2: Clarify the role of SIRT1 in embryonic and adult embryogenesis in vivo using a 
SIRT1 mutant mouse model. 
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MATERIALS AND METHODS 
Part I 
Cell culture and differentiation 
Mouse ES cell line R1 and SIRT1
-/-
 mES cells derived from R1 parental cells (A kind gift 
from Dr. McBurney, Ottawa, Canada) were cultured as reported (Kyba, Perlingeiro et al. 
2002) on irradiated mouse embryonic fibroblasts in Dulbecco modified Eagle medium 
with 15% fetal bovine serum (FBS) (Hyclone Laboratories, Logan, UT), 1000 U/mL LIF 
(Chemicon International, Temecula, CA), 10 U/μl penicillin/streptomycin (Invitrogen, 
Carlsbad, CA), L-Glutamine 200 mM (100×) (Gibco, Carlsbad, CA), 0.1 mM 
nonessential amino acids (Invitrogen, Carlsbad, CA), and 0.1 mM β-mercaptoethanol 
(Invitrogen, Carlsbad, CA) at 37ºC / 5% CO2. Media was changed daily, and cultures 
passaged every 2 to 3 days. 
OP9 stromal cells (ATCC, Manassas, VA) were maintained in α-MEM medium 
supplemented with 10 U/μl penicillin/streptomycin, L-Glutamine 200 mM (100×) 
(Gibco), and 20% heat-inactivated fetal calf serum (Invitrogen). Cells were passaged 
every 4 to 6 days. OP9 coculture was performed as described (Kyba, Perlingeiro et al. 
2002).  
For primary differentiation assays, ES cells were plated in bacterial grade Petri dishes at 
3000 cells/mL in 0.9% methylcellulose-based differentiation media composed of Iscove 
Modified Dulbecco Medium (IMDM) plus 15% differentiation FBS (StemCell 
Technologies, Vancouver, BC), 2 mM penicillin/streptomycin (Invitrogen), L-Glutamine 
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200 mM (100×) (Gibco), 5% protein-free hybridoma medium (PFHM-II) (Gibco), 200 
mg/mL iron-saturated holo-transferrin (Sigma, St. Louis, MO), 5 mg/mL ascorbic acid 
and 450 μM monothioglycerol (Sigma). After withdrawal of ES cells from feeder cells 
and LIF, cells were incubated for 6 days at 37ºC in 5% CO2. EBs were viewed by light 
microscopy and examined for presence of hemoglobin as assessed initially by the red 
colored EBs. 
For secondary plating assays, EBs were digested with 0.25% trypsin (Gibco) followed by 
passaging cells through a 20-gauge needle 2-3 times. Cells were plated at 25,000 
cells/mL with erythropoietin (EPO; 5 U/mL; R&D Systems, Minneapolis, MN), Stem 
Cell Factor (SCF; 100 ng/mL; R&D system) and Interleukin-3 (IL-3; 1 ng/mL; R&D 
Systems) for assessment of definitive erythroid progenitor cells, or with EPO (5 U/mL), 
SCF (100 ng/mL), IL-3 (1 ng/mL), granulocyte-macrophage colony-stimulating factor 
(GM-CSF; 10 ng/mL; R&D Systems), and macrophage colony-stimulating factor (M-
CSF; 5 ng/mL; R&D Systems) for analyses of mixed and granulocyte-macrophage 
colony assays. For detection of primitive erythroid progenitors, cells were plated with 15% 
plasma-derived serum (Animal Technologies, Antech, TX) and Epo (5 U/ml) (Palis, 
Robertson et al. 1999). 
Blast colony-forming cell (BL-CFC) assays  
EBs were collected at different days post differentiation in liquid suspension culture, 
washed in PBS, and treated with 0.25% trypsin for 3 minutes at 37ºC. EBs were 
dissociated into single cells by passage two-three times through a 23-gauge needle and 
plated at 3 × 10
4 
cells in 1ml of methycellulose medium with 10% FCS, 10% FBS, SCF 
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(100 ng/mL), 25% D4T endothelial cell-conditioned medium (Kennedy, Firpo et al. 
1997), 5 ng/ml mouse Vascular Endothelial Growth Factor (VEGF; R&D Systems), 10 
ng/ml human IL-6 (R&D Systems) and IMDM. Cells were maintained at 37ºC in a 
humidified 5% CO2 incubator. After 3-4 days, developing BL-CFCs were counted.  
Generation of Hematopoietic cells from BL-CFCs 
BL-CFC were plucked and replated into secondary methycellulose media containing IL-3, 
IL-6, Epo and SCF. Cultures were maintained as described above and secondary 
hematopoietic colonies were scored at 7-10 days of growth (Kennedy, D'Souza et al. 
2007). 
Generation of Endothelial cells from BL-CFCs 
Individual BL-CFC were picked and transferred to matrigel-coated microtiter cells 
containing IMDM with 10% FCS, 10% horse serum (GIBCO), VEGF (5 ng/ml), insulin 
growth factor-1 (IGF-1, 10 mg/ml), Epo (2 U/ml, R&D Systems), basic fibroblast growth 
factor (bFGF, 10 ng/ml), IL-11 (50 ng/ml; R&D Systems), SCF (100 ng/ml), endothelial 
cell growth supplement (ECGS, 100 µg/ml; Collaborative Research), L-glutamine (2 
mM), and 4.5×10
-4
 M monothiglycerol (MTG). After 3-4 days in culture, nonadherent 
cells were removed and adherent cells were cultured for an additional 1-2 weeks in 
IMDM with 10% FCS, 10% horse serum, VEGF (5 ng/ml), IGF-1 (10 ng/ml), bFGF (10 
ng/ml), ECGS (100 µg/ml), L-glutamine (2 mM), and 4.5×10
-4
 M MTG (Kennedy, 
D'Souza et al. 2007). 
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Cell Staining 
BL-CFCs were plucked onto prewashed glass cover slips that were coated with a thin 
layer of matrigel and cultured in 12-well dishes in medium containing both hematopoietic 
and endothelial cytokines, as described above. Four to seven days following the initiation 
of the cultures, the nonadherent hematopoietic cells were removed and the adherent cells 
were cultured for an additional 1-2 weeks in medium containing only endothelial growth 
factors (see last section). For fluorescence analysis, adherent cells were initially cultured 
in the presence of 10 µg/ml of Dil-Ac-LDL (Biomedical Technologies; Stoughton, MA) 
at 37ºC for 2 hours. Following this incubation, the cells were washed three times and 
fixed for 10 minutes in PBS containing 3% paraformaldehyde and 3% sucrose. The fixed 
cells were washed two to three times and incubated with fluorescein isothiocyanate-
mouse anti-CD144 (BD Pharmingen, San Diego, CA) for 1 hour. Following this staining, 
cells were washed again (five times) and the coverslip with the cells was mounted onto a 
slide for analysis. The images were acquired with a digital confocal microscope using the 
Zeiss LSM-510 software program (Oberkochen, Germany). 
Vascular sprout formation assay 
Aliquots of 200 μL Matrigel (BD Pharmingen) were added to each precooled well of 24-
well culture plates and incubated at 37ºC until gelation occurred as described (Feraud, 
Cao et al. 2001). Then 50, day-6 EBs were suspended in 200 μL medium containing 15% 
FBS, 0.1 mM β-mercaptoethanol (Invitrogen), 2 mM glutamine, 5 ng/mL recombination 
murine VEGF, and 50 μgmL endothelial cell growth supplement (BD pharmingen) and 
cells were seeded on matrigel. EBs were incubated at 37ºC in a 5% CO2, 95% air 
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atmosphere. EBs were scored in blinded fashion according to 4 standard classes based on 
vascular sprout formation: I, no sprout formation; II, few sprouts; III, many sprouts but 
no network; and IV, many sprouts with network (Feraud, Cao et al. 2001). Another 
aliquots of day 6 EBs were suspended in IMDM Glutamax and mixed with collage 
culture medium (Invitrogen) at a final concentration of 50 EBs/mL. Final composition of 
freshly prepared collagen-based culture medium was as follows: IMDM containing 1.25 
mg/mL type I rat tail collagen (BD Biosciences, San Jose, CA), 15% fetal calf serum, 450 
mM monothioglycerol, 10 μg/mL insulin, 50 U/mL streptomycin, and 50 U/mL penicillin. 
After thorough mixing of EBs into collagen-based medium, 1.2 mL were dispensed into 
35-mm bacterial Petri dishes. Cultures were then incubated for 8 days for analysis of their 
vascular development (Feraud, Cao et al. 2001). All Cell cultures were done under both 
normoxic (~20% O2) and lower O2 (5% O2) conditions. 
Flow cytometry analysis for surface markers 
Single cell suspensions were prepared from WT and SIRT1
-/-
 EBs. Staining was done as 
described previously (Fehling, Lacaud et al. 2003). Briefly, one million cells were 
resuspended in FACS staining buffer (PBS +2% FBS) and were stained with c-kit-APC 
(2B8, eBioscience), and Flk-1-PE (BD Bioscience), incubated for 30 minutes in the dark 
at 4ºC, washed twice with PBS containing 2% BSA, and resuspended in PBS containing 
1% paraformaldehyde for analysis by flow cytomery of FACSCalibur (Becton Dickinson, 
Sunnyvale, CA). Approximately 10,000 events were collected for each sample. 
Real-time PCR analysis 
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Total RNA was extracted from each sample using TRIzol reagent (Invitrogen). RNA was 
treated with RNase-free DNase for 20 min (Ambion, Austin, TX) at room temperature 
before reverse transcription with Superscript II RT (Invitrogen, Carlsbad, CA). An RT
2 
Profile Custom PCR Array was used to simultaneously examine mRNA levels of 48 
genes, including three “housekeeping genes” in 96-well plates according to the 
manufacturer (SA Biosciences, Frederick, MD). Real-time PCR was performed on an 
MX30000P Stratagene machine (Stratagene, La Jolla, CA) with SYBR Green PCR 
Master Mix (SA Biosciences). PCR conditions consisted of a 10 min hot start at 95ºC, 
followed by 40 cycles of 15 seconds at 95ºC and 1 min at 60ºC. The average threshold 
cycle for each gene was determined from triplicate reactions and three independent 
experiments. Values were exported to a template Excel file for analysis. Analyses of raw 
data were done through the SA biosciences data analysis web portal 
(http://www.sabiosciences.com/pcr/arrayanalysis.php).  
Western blot analysis 
Protein extracts from 2×10
6
 mES cells were prepared and immunoblots performed 
according to standard techniques. Briefly, samples were loaded on a 4-12% sodium 
dodecyl sulfate (SDS)-polyacrylamide gel (Invitrogen). After transfer of proteins onto 
polyvinylidene difluoride membrane (Bio-rad, Hercules, CA), nonspecific binding was 
blocked by incubation with Tris-buffered saline/Tween 20 (25 mM Tris, 25 mM glycine, 
0.1% SDS, and 0.1% Tween-20) containing 2% BSA. The membrane was then probed 
with antibodies against Erk (Cell Signaling Technology, Boston, MA) and β-actin (Cell 
Signaling Technology). Next, the membrane was incubated with a horseradish-
peroxidase-conjuagted secondary antibody and developed with enhanced 
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chemilluminescence PLUS reagent from (Amersham, Piscataway, NJ). To determine that 
amounts of protein in each lane were comparable, the membrane was cut at about the 
expected molecular weight of target proteins and β-actin. The cut membranes were 
respectively probed with antibodies against target proteins or a rabbit polyclonal antibody 
against β-actin. 
Alkaline Phosphatase Staining 
Murine ES cells were cultured with 2-ME and LIF for 3 days to obtain spheroidal 
colonies. Cells were washed with PBS (BioWhittaker) and fixed with 4% 
paraformaldehyde (Sigma) in PBS for 5 min. After washing, Cells were stained with an 
Alkaline Phosphatase Staining Kit (Chemicon, Temucula, CA) at room temperature for 
15 min in the dark. Cells were washed with PBS again, and colonies were visualized 
using an Olympus Microscope. 
Flow Cytometry Analysis of Oct-4, CD9 and KLF-4 
An aliquot of 1 × 10
6
 cells was washed in ice-cold PBS containing 2% FCS serum (PBS-
2% FCS) and incubated with anti-mouse CD16/CD32 receptor monoclonal antibody at 1 
µg/100 µl (BD Biosciences) to block non-specific binding of immunoglobulins to the 
mouse FcIII/II receptors. Cells to be stained for Oct-4 and KLF-4 were fixed with 100 µl 
of IC fixation buffer (eBioscience, San Diego, CA) for 30 min at room temperature, 
washed one time with PBS-2% FCS, permeabilized with permeabilization buffer 
(eBioscience), and incubated with a 1:100 dilution rabbit-mouse Oct3/4 polyclonal 
antibody (Chemicon) or rabbit-mouse KLF-4 polyclonal antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) for 30 min at room temperature. Cells were washed two 
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times with 1 ml of PBS-2% FCS followed by staining with 1:100 dilution of fluorescein 
isothiocyanate (FITC): goat anti-rabbit IgG antibody (Santa Cruz Biotechnology). Finally, 
the cells were washed two times with PBS-2% FCS and resuspended in PBS-2% FCS for 
analysis on a FACScan flow cytometer (Becton Dickinson). Cells analyzed for CD9 were 
incubated first with a 1:100 dilution of anti-mouse CD9 (BD Pharmingen) for 40 min at 
4ºC, washed two times with ice-cold PBS-2% FCS, and incubated with a 1:500 dilution 
of FITC: goat-anti rat IgG antibody (Santa Cruz Biotechnology). 
Part II 
Progenitor assays 
    Primitive erythroid yolk sac (E8-E8.25) progenitors. Treatment with 0.25% 
collagenase (Sigma) plus 20% FCS for 10 mintues at 37ºC with vigorous pipetting 
resulted in single cells which were plated with 15% plasma-derived serum (Animal 
Technologies, Tyler, TX) and Epo (5 U/mL). Colonies were counted at day 5. (Palis, 
Robertson et al. 1999) Embryos were generated as described (Wang, Sengupta et al. 
2008). 
Adult marrow hematopoietic progenitors. Fifty thousand bone marrow nucleated cells 
were plated onto 35-mm Petri dishes in methylcellulose with 30% FBS (Hyclone, Logan, 
UT), 1 U/ml hu Epo, 5% pokeweed mitogen mouse spleen cell conditioned medium, and 
50 ng/ml murine SCF. (Broxmeyer, Orschell et al. 2005) Colonies were scored after 7 
days at ~20% or 5% O2. Mating of mice was conducted as described (Wang, Sengupta et 
al. 2008). 
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Genotyping of Mice 
The animals were genotyped by PCR using primer 1, 5‟- TCCTTGCCACAGTCACTCA 
C-3‟; primer 2, 5‟- ACAGTCCCATTCCCATACC-3‟; and primer 3, 5‟-CATCTAAACT 
TTGTTGGCTGC-3‟. Primers 1 and 3 are located within intron 4 and amplify the wild-
type allele (660 bp). Primer 2 is located within exon 7; the combination of primers 1 and 
2 amplifies the deleted allele (716 bp).  
Statistical Analysis 
Significant differences were determined by student t-test comparisons for at least 3 
experiments each, with triplicates performed for each experiment. 
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RESULTS 
 
Part I: SIRT1 deficiency compromises hematopoietic differentiation of mouse 
embryonic stem (mES) cells 
 
SIRT1 is dispensable for self-renewal of mES cells 
Recently our lab demonstrated that SIRT1 regulates apoptosis and Nanog expression in 
mES cells in the presence of LIF and 2ME-withdrawal-induced increase in reactive 
oxygen species by controlling p53 subcellular localization (Han, Song et al. 2008). As a 
follow on to these studies, we evaluated the effect of SIRT1
-/-
 on self-renewal and 
differentiation of mES cells in the presence of 2-ME, but absence of LIF. First, we 
explored the role of SIRT1 in the self-renewal of mES cells. ES cell self-renewal depends 
on a stoichimometric balance among various signaling molecules. There are several 
molecular markers and transcription factors defining stemness of mES cells including 
Rex-1 (Hosler, Rogers et al. 1993), CD9, Oct4, Klf-4, SSEA-1 et al (Walker, Chang et al. 
2010). Undifferentiated mES cells also possess enzyme activities for alkaline 
phosphatase (AP) (Wobus, Holzhausen et al. 1984). Therefore, we assessed AP, CD9, 
Klf-4 and Oct4 expression in WT R1 and SIRT1
-/-
 mES cells. Alkaline phosphatase is a 
hydrolase enzyme responsible for dephosphorylating molecules such as nucleotides, 
proteins, and alkaloids under alkaline conditions. When fixed ES cells are stained with 
AP, undifferentiated cells appear red or purple, whereas differentiated cells appear 
colorless. When maintained with LIF and mouse embryonic fibroblast feeder layer cells, 
both WT and SIRT1
-/-
 mES cells appear red, suggesting AP expression and an 
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undifferentiated state (Figure 6). Furthermore, we examined the expression of the 
molecular marker CD9, and pluripotent transcription factors Oct4 and Klf-4. WT and 
SIRT1
-/-
 mES cells showed similar expression of these markers (Figure 7). Taken together, 
these data suggest that SIRT1 is dispensable for the self-renewal of mES cells. 
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Figure 6 
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Figure 6: Alkaline phosphatase staining of WT R1 and SIRT1
-/-
 cells when cultured 
with 2-ME and LIF.  
One thousand WT and SIRT1
-/- 
cells were cultured in medium containing LIF on a MEF 
feeder layer for 3 days to obtain spheroidal colonies. Then cells were stained with an 
Alkaline Phosphatase Staining Kit (Chemicon, Temucula, CA) at room temperature and 
colonies were visualized using an Olympus Microscope. 
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Figure 7 
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Figure 7: Expression of CD9, Oct-4 and Klf-4 in WT and SIRT1
-/- 
mES cells were 
analyzed by flow cytometry.  
WT and SIRT1
-/- 
cells were cultured in medium containing LIF on a MEF feeder layer. 
After 3 days, 1 × 10
6
 of both cells were collected and stained with anti-mouse CD9, Oct4 
and Klf-4. One representative of three histograms for each marker is shown in the figure. 
For CD9, the light grey line is isotype control staining, while the shaded line is the anti-
CD9 staining. For Oct-4, the green line is isotype control staining, while the shaded blue 
line is the anti-Oct-4 staining. For Klf-4, the green line is isotype control staining, while 
the shaded red line is the anti-Klf-4 staining. 
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Delayed/Defective hemangioblast development in absence of SIRT1 
With removal of LIF and in the absence of feeder layer cells, ES cells grow into EBs, 
which generate hematopoietic and endothelial progeny, recapitulating development of 
those populations in the yolk sac (Keller 1995). Endothelial and hematopoietic lineages 
develop in parallel, and are most intertwined in yolk sac blood islands and the dorsal 
aorta in the embryo (Jaffredo, Gautier et al. 1998; Lancrin, Sroczynska et al. 2009). In 
both the yolk sac and embryonic dorsal aorta, blood vessels give rise to the hematopoietic 
elements via specialized hemogenic endothelium (Chen, Yokomizo et al. 2009). 
Although SIRT1 regulates vascular endothelial homeostasis controlling angiogenesis, 
vascular tone and endothelial dysfunction (Mattagajasingh, Kim et al. 2007; Potente, 
Ghaeni et al. 2007), little information is available on SIRT1 activities in embryonic and 
adult stages of hematopoietic and endothelial development. A common progenitor of 
hematopoietic and endothelial cells was identified as the hemangioblast by the BL-CFC 
assay. To assess whether SIRT1 plays a role in hemangioblast development, we tested the 
ability of SIRT1 deficient ES cells to give rise to blast colonies by BL-CFC assay. BL-
CFCs were analyzed on days 3, 3.5, 4, 5, 5.5, 6 and 7 respectively. As shown in Figure 
8A, WT EBs generated BL-CFCs from day 3 and peaked on day 4. SIRT1
-/-
 EBs did not 
generate significant numbers of typical blast colonies until day 4; but were significantly 
lower than BL-CFCs generated by WT EBs. SIRT1
-/-
 BL-CFCs peaked on day 5.5. No 
colonies were generated in both cell lines on day 7. BL-CFC development in SIRT1
-/- 
EBs 
is thus restricted to a narrower and later window of time, than found in WT EBs. 
Meanwhile, transitional colonies, which have similar morphology as those developed in 
68 
 
Scl
-/-
 ES cells (Figure 9B) (Robertson, Kennedy et al. 2000) and secondary embryonic 
bodies were most readily detected in the SIRT1
-/-
 cultures (Figure 8A, C). 
Flk1 is the receptor 2 for VEGF (VEGF-R2). Others demonstrated that Flk-1 is expressed 
on BL-CFCs, and onset of Flk1 corresponds to BL-CFC development. c-Kit is expressed 
on ES cells and populations found at early stages of EB development (Kennedy, Firpo et 
al. 1997; Choi, Kennedy et al. 1998); its expression is down-regulated following 
differentiation. Beyond the hemangioblast stage, c-Kit is co-expressed with Flk1 marking 
establishment of hematopoiesis (Lacaud, Kouskoff et al. 2004). To further assess if 
SIRT1
-/-
 affects in vitro developmental potential of ES cells into hemangioblast, we 
analyzed temporal expression patterns of cell surface Flk1 and c-Kit by flow cytometry. 
As shown in Figure 8, a distinct Flk1
+
, c-Kit
-
 cell population (Flk1
+
/c-Kit
-
) emerged in 
WT EBs by day 3.5 of differentiation, and increased during the next 24 hours. This 
window defines the hemangioblast stage of development, as demonstrated by presence of 
BL-CFCs at those times. In SIRT1
-/-
 EBs, emergence of a distinct Flk1
+
/c-Kit
-
 population 
was reproducibly detected at least 12 hours later than in WT EBs, and the percent of 
SIRT1
-/-
 Flk
+
/c-Kit
-
 cells was significantly decreased on days 3.5 and 4. The average 
percentage ± SEM in 3 independent experiments of Flk1
+
/c-kit
- 
cells was: 27.7±4.6 in 
SIRT1
+/+
 and 2.3±1.3 in SIRT1
-/-
 EBs (p value=0.007) at day 3.5 of differentiation, 
45.7±3.7 in WT and 3.8±0.8 in SIRT1
-/-
 EBs (p value=0.001) at day 4; by day 5.5, there 
was a switch with 14.8 ±1.8 in WT and 31.7±3.7 in SIRT1
-/-
 EBs (p value=0.006). 
Delayed emergence of Flk1
+
/c-Kit
- 
cells in SIRT1-/- EBs was consistent with delayed BL-
CFC development in SIRT1
-/-
 EBs (Figure 8A). This delay appears to result from 
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immature differentiation of the SIRT1
-/-
 ES cells as kinetics of decline in transitional 
colonies and secondary EBs, is delayed compared to WT ES cells (Figure 8A, C). 
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Figure 8 
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Figure 8: Blast cell colony development from WT and SIRT1
-/-
 ES cells.  
(A) Kinetics of blast and transitional colony development in WT and SIRT1
-/-
 EBs. Data 
are shown as mean ± SD. N=3; *, p<0.01.  Days (D) of differentiation are indicated. ∆= 
no colony grown. (B) The morphology of blast colonies, transitional colonies and 
secondary EBs formed in the culture  system of BL-CFC assay (Robertson, Kennedy et al. 
2000).  (C) Secondary EB colonies generated by WT and SIRT1
-/-
 EB cells. Days of 
differentiation are indicated. Data are shown as mean ± SD. N=3; *, p<0.01. 
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Figure 9 
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Figure 9: FACS analysis of Flk1 and c-Kit expression on WT and SIRT1
-/-
 EB-
derived cells.  
WT and SIRT1
-/-
 EBs of day 3.5, 4, 4.5, 5, 5.5, 6 and 7 were collected at the time points 
and then dissociated into single cells. Viable cell counts were taken by trypan blue 
exclusion counting. One million of WT and SIRT1
-/-
 cells were collected and stained with 
anti-mouse Flk-1 and c-Kit. After staining, the expression of Flk-1 and c-Kit in WT and 
SIRT1
-/-
 EB-derived cells were analyzed by flow cytometry. Days of differentiation are 
indicated. Numbers in each quadrant represent the percent of total population in each 
fraction. Representative of three independent experiments. 
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SIRT1-deficient BL-CFCs have reduced hematopoietic, but unaffected endothelial, 
replating potential 
Hemangioblasts generate blast colonies in vitro displaying hematopoietic and endothelial 
potential (Choi, Kennedy et al. 1998). To assess developmental potential of blast colonies, 
single WT
 
and SIRT1
-/- 
BL-CFCs were replated, transferred to microtiter wells, and 
cultured for 4 days to determine their potential to generate adherent (endothelial) and 
nonadherent (hematopoietic) cells. Considering the peak of blast colony formation in WT 
and SIRT1
-/-
 ES cells, day 4 of WT and day 5.5 of SIRT1
-/-
 blast colonies were used 
respectively. After expansion (Figure 10A), nonadherent cells of each well were replated 
in methycellulose to assay hematopoietic potential. Adherent cells were cultured for an 
additional week and then harvested and analyzed for expression of genes associated with 
the endothelial lineage. Endothelial cells express vascular endothelial cadherin (VE-
cadherin, CD144) and take up acetylated low-density lipoprotein (Ac-LDL) (Perlingeiro, 
Kyba et al. 2003). Colonies from WT
 
and SIRT1
-/-
 cells generated both types of cells. 
Adherent cells derived from WT
 
and SIRT1
-/-
 BL-CFCs, both displayed Dil-Ac-LDL 
uptake (red) as well as CD144 expression (green) (Figure 10B), indicating that adherent 
populations derived from WT
 
and
 
SIRT1
-/-
 individual blast colonies are of the endothelial 
lineage. Replating revealed that whereas WT
 
and
 
SIRT1
-/-
 generated endothelial cells at a 
similar frequency, the nonadherent populations from SIRT1
-/-
 blast colonies contained 
fewer secondary hematopoietic precursors with colony-forming potential (Figure 10C). 
Transitional colonies derived from SIRT1
-/- 
ES cells were also replated and analyzed. 
They were able to give rise to adherent (endothelial) populations (data not shown). 
75 
 
However, they did not generate the round nonadherent (hematopoietic) cells after 4-day 
culture, which suggests their inability to generate hematopoietic progeny. 
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Figure 10 
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Figure 10: Evaluation of the hematopoietic and endothelial potentials of BL-CFCs 
derived from WT and SIRT
-/-
 cells.  
(A) The morphology of adherent and nonadherent cells generated from single blast 
colony after expansion. (B) Immunostaining and Dil-Ac-Low density lipoprotein (LDL) 
uptake of adhesive cells generated from a single blast colony from WT and SIRT1
-/-
 EB-
derived cells. VE-Cadherin expression is indicated by green fluorescence and LDL 
uptake by red fluorescence. (C) Evaluation of the hematopoietic and endothelial 
potentials of BL-CFCs. The number of colonies that yielded secondary CFCs or adherent 
endothelial cells is divided by the total number of replated colonies. Bars represent 
standard error of the mean number from at least 3 experiments. Data are shown as mean 
± SEM. N=3; *, p<0.05. 
 
 
 
 
 
 
 
 
78 
 
Hematopoietic cell differentiation of SIRT1
-/-
 cells is defective 
Defective hematopoietic development of blast colonies in SIRT1
-/-
 EBs prompted us to 
investigate their primitive and definitive hematopoietic potential. ES cells were 
differentiated into EBs for 4-12 days, at which time cells were disrupted and plated for 
primitive erythroid (EryP) and definitive colonies. In addition to delay of hemangioblast 
development and limited hematopoietic potential from SIRT1
-/-
 blast colonies, SIRT1
-/-
 
EBs displayed delayed and greatly decreased hematopoietic commitment as demonstrated 
by later generation of Flk1
+
/c-Kit
+
 cells (Figure 9) and presence of primitive precursors 
by day 5.5 of differentiation compared to day 4 for WT
 
cells (Figure 11A). Low oxygen 
promotes erythropoiesis and other forms of hematopoiesis. Because low oxygen tension 
affects cellular redox state and SIRT1 is a redox-sensitive molecule (Caito, 
Rajendrasozhan et al. 2010), we assessed the ability of WT
 
and
 
SIRT1
-/-
 EBs to generate 
erythroid precursors under lowered 5% O2. Lowered O2 allowed increased detection of 
EryP colonies from both WT
 
and
 
SIRT1
-/-
 cells. However, even under lowered O2 no 
SIRT1
-/-
 cell-derived colonies were noticeable until day 5.5, even though the number of 
WT colonies was greatly enhanced under the lowered O2. The delay in generation of 
SIRT1
-/-
 EryP colonies was thus readily apparent at both oxygen tensions (Figure 11A, B; 
note different scales for colony numbers). The morphology of definitive hematopoietic 
progenitor cells derived from mES cells are demonstrated in Figure 12. We observed 
somewhat smaller, but still significant decreases in numbers of definitive granulocyte 
macrophage (CFU-GM) and multipotential (CFU-GEMM) progenitor cells obtained from 
SIRT1
-/-
 compared to WT
 
 cells at day 6 and 8 (Figure 13A, B). But the differences of 
CFU-GM (1.6620%O2 versus 2.565%O2 on day 6, 1.5320%O2 versus 1.795%O2 on day 8) 
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between WT
 
and
 
SIRT1
-/-
 EBs were greater at low O2. Differences in fold changes of cells 
grown at normoxia and 5% O2 suggest that SIRT1
-/-
 cells are not as responsive as WT 
cells to the enhancing effect of lowered O2 tension. In addition, SIRT1
-/-
 cells had higher 
numbers of secondary EBs (Figure 13A, B). We also evaluated mRNA levels of both 
embryonic and adult globin genes and observed reduction in expression of both genes in 
SIRT1
-/-
 cells (Figure 14A, B). These results suggest a delay/defect in hematopoietic 
commitment upon SIRT1
-/-
 ES cell differentiation. 
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Figure 11 
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Figure 11: Primitive erythroid colonies generated from WT and SIRT1
-/-
 EB-derived 
cells under normoxia (20% O2) and lower O2 (5% O2) tension.  
(A) Primitive erythroid colonies generated from day 0 to day 12 WT and SIRT1
-/-
 EB-
derived cells under normoxia (20% O2) tension. Data are shown as mean ± SD. N=3; *, 
p<0.05. Morphology of primitive erythroid colonies formed from WT and SIRT1
-/-
 EBs 
was shown on the right corner. Image acquisition details: Nikon Diaphot microscope, 
10×/0.25 numeric aperture objective lens, Nikon F3 camera, NIS-Elements D2.30 
software. (B) Primitive erythroid colonies generated from day 0 to day 12 WT and SIRT1
-
/-
 EB-derived cells under lower (5%) O2 tension. At each time point, dissociated EB-
derived cells were measured by trypan blue exclusion counting, and cells were plated in 
triplicate in methycellulose colony assays. The type of colonies was evaluated based on 
their distinguished morphology and bright red color observed under light microscope. 
Data are shown as mean ± SD. N=3; *, p<0.05. Days (D) of differentiation are indicated. 
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Figure 12 
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Figure 12: Morphology of definitive erythroid progenitors (Ery-D), definitive 
GEMM, multilineage progenitors of granulocytes, erythroid cells, macrophages, 
megakaryocytes; GM, multilineage progenitors of granulocytes and macrophages 
derived from mouse embryonic stem cells.  
Ery-D progenitors were identified as they appear dark red color. GEMM progenitors 
were evaluated as they are composed of red color cells in the central, and round and 
refractive cells in the periphery of the colonies. GM progenitors were distinguished by 
the round and refractive cells. Image acquisition details: Nikon Diaphot microscope, 
10×/0.25 numeric aperture objective lens, Nikon F3 camera, NIS-Elements D2.30 
software. 
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Figure 13 
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Figure 13: Definitive GEMM, multilineage progenitors of granulocytes, erythroid cells, 
macrophages, megakaryocytes; GM, multilineage progenitors of granulocytes and 
macrophages; and secondary EBs generated from WT and SIRT1
-/-
 EB-derived cells 
under normoxia condition and lower (5%) O2 tension at day 6 (A) and day 8 (B). At each 
time point, dissociated EB-derived cells were measured by trypan blue exclusion 
counting, and cells were plated in triplicate in methycellulose colony assays. The types of 
colonies were evaluated based on their distinguished morphology observed under light 
microscope. Data are shown as mean ± SD. N=3; *, p<0.05. 
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Figure 14 
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Figure 14: Relative mRNA expression of embryonic globin (marker for Ery-P) (A) and 
adult globin (marker for Ery-D) (B) genes from WT and SIRT1
-/-
 day 0, 2, 4, 6, 8, and 10 
EBs by real-time RT-PCR. Error bars indicate standard deviations from the average of 
three independent experiments, each performed in triplicate; ***, p<0.001, **, p<0.01, *, 
p<0.05.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
88 
 
Deletion of SIRT1 results in defective formation of a vascular-like network in vitro 
To assess a role for SIRT1 in angiogenesis, vascular sprout formation developed from 
day 6 EBs was assessed using a three dimensional spheroidal assay. WT
 
and SIRT1
-/-
 EBs 
developed similar endothelial outgrowths when embedded into collagen gel (Figure 15A). 
Quantitative analysis on the percentage of angiogenic EBs revealed that loss of SIRT1 
expression does not significantly affect endothelial sprout formation (Figure 15B). 
However, SIRT1
-/-
 cells did not form a full vascular-like network in vitro (Figure 16A); 
they had significantly fewer class III (many sprouts but not network) and class IV 
(abundant networked tubules) vascular sprout formations than WT
 
EBs (Figure 16B). 
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Figure 15 
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Figure 15: Effect of SIRT1 deletion on in vitro vascular sprout formation in 
differentiating EBs.  
(A) Representative micrographs of three-dimensional in vitro angiogenesis assays with 
collagen gel-embeded spheroids generated from WT or SIRT1
-/-
 day 6 EBs. (B) Analysis 
of the percentage of angiogenic EBs was performed after 8 days of secondary culture in 
collagen gel. Data are shown as mean ± SEM; N=3. Image acquisition details: Nikon 
Diaphot microscope, 10×/0.25 numeric aperture objective lens, Nikon F3 camera, NIS-
Elements D2.30 software. 
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Figure 16 
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Figure 16: Effect of SIRT1 deletion on in vitro vascular sprout formation in 
differentiating EBs. 
 (A) Representative micrographs of in vitro matrigel assays with WT or SIRT1
-/-
 day 6 
EBs. Image acquisition details: Nikon Diaphot microscope, 10×/0.25 numeric aperture 
objective lens, Nikon F3 camera, NIS-Elements D2.30 software. (B) Percentage of each 
class of vascular sprouting (See methods). Briefly, EBs were incubated EBs were scored 
in blinded fashion according to 4 standard classes based on vascular sprout formation: I, 
no sprout formation; II, few sprouts; III, many sprouts but no network; and IV, many 
sprouts with network (Feraud, Cao et al. 2001). Data are shown as mean ± SEM. N=3; *, 
p value=0.01-0.04. 
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SIRT1 deficiency affects expression of genes involved in mES cell differentiation 
and hematopoietic commitment 
Given the inappropriate differentiation and reduced hematopoietic potential of SIRT1
-/-
 
ES cells, we collected RNA from EBs and quantified transcript levels of genes that might 
shed light on loss of ES cell differentiation potential. This includes genes involved in 
development of epiblast-like cells, onset of mesoderm development, and markers for 
other germ layers in EBs at different stages. Expression of mRNA for Oct4 (Pou5f1) and 
Nanog, well known pluripotency transcription factors, were rapidly shut down upon 
differentiation of WT
 
cells, consistent with rapid loss of potential to generate secondary 
EBs. However, down-regulation of Oct4 and Nanog was remarkably delayed in SIRT1
-/-
 
cells upon differentiation (Figure 17A). Notably Fgf5, a gene expressed in the epiblast of 
early embryos and down-regulated after pre-hemangioblast mesoderm stage (Fehling, 
Lacaud et al. 2003) was increased and maintained in SIRT1
-/-
 EBs. Meanwhile, 
expression of T and Wnt3, indicative of mesoderm commitment and development, was 
delayed and sustained (Figure 17B). These gene expression patterns, combined with the 
results of blast and transitional colony formation in SIRT1
-/-
 EBs, indicates the earliest 
stages of hemangioblast commitment are occurring, but not fully developed in SIRT1
-/-
 
ES cells at the appropriate time points. We further analyzed expression of Scl/Tal-1, a 
transcription factor essential for commitment of mesoderm to hematopoiesis (Robertson, 
Kennedy et al. 2000). It was delayed at least 24 hours and greatly decreased on days 4, 6, 
and 8 in SIRT1
-/-
 EBs (Figure 17B), which is consistent with the interpretation that 
progression of hematopoietic commitment was compromised in SIRT1
-/-
 cultures. 
Trophectoderm marker Cdx2 (Figure 18B), and molecular markers for 
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endoderm/mesoderm GATA-4, Sox17, and GATA-6 showed delayed expression in 
SIRT1
-/- 
cells, but at later days, there was no difference between the expression of these 
genes in WT
 
and
 
SIRT1
-/-
 EBs (Figure 18A). Expression of the cardiac lineage marker 
Nkx2.5 showed no difference (Figure 18A). In addition, the hematopoietic-specific gene 
GATA-1 was reduced in day 5 SIRT1
-/-
 EBs. Notably, GATA-1 at late stage and Runx-1 
were non-significantly decreased (Figure 19A, B), suggesting that SIRT1 may largely 
affect early stages of ES cell commitment to hematopoietic lineage. Together, these data 
suggest that SIRT1 is critically involved in gene expression for early commitment and 
differentiation.  
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Figure 17 
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Figure 17: Gene expression analysis of WT and SIRT1
-/-
 EBs by real-time PCR 
analysis.  
(A) Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis of 
stem cell marker Oct4 and Nanog mRNA levels in day 0-10 WT and SIRT1
-/-
 EBs. (B) 
qRT-PCR analysis of mRNA levels of epiblast marker Fgf5, mesoderm markers T, Wnt3 
and transcription factor Tal1/Scl in day 0-10 WT and SIRT1
-/-
 EBs. Day (D) 0 represents 
undifferentiated ES cells. Graphs were plotted in logarithmic scale. Data are relative to 
WT D0 control and mRNA levels of each gene were compared between WT and SIRT1
-/-
 
EBs at each time point. Results were the average of three independent experiments, each 
performed in triplicate. *, p<0.05. 
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Figure 18 
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Figure 18: Gene expression analysis of WT and SIRT1
-/-
 EBs by real-time PCR 
analysis.  
(A) qRT-PCR analysis of mRNA levels of trophectoderm marker Cdx2, neuroectoderm 
marker Sox1 and cardiac lineage marker Nkx2-5 in day 0-10 WT and SIRT1
-/-
 EBs. (B) 
qRT-PCR analysis of mRNA levels of endoderm/mesoderm markers GATA-4, GATA6 
and Sox17 in day 0-10 WT and SIRT1
-/-
 EBs. Day (D) 0 represents undifferentiated ES 
cells. Graphs in (A-D) were plotted in logarithmic scale. Data are relative to WT D0 
control and mRNA levels of each gene were compared between WT and SIRT1
-/-
 EBs at 
each time point. Results were the average of three independent experiments, each 
performed in triplicate. *, p<0.05. 
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Figure 19 
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Figure 19: qRT-PCR analysis of mRNA levels of genes Gata-1 (A) and Runx-1(B) in 
day 0, day 4-7 WT and SIRT1
-/-
 EBs. Data are relative to WT D0 control and mRNA 
levels of each gene were compared between WT and SIRT1
-/-
 EBs at each time point. 
Results were the average of three independent experiments, each performed in triplicate. 
*, p<0.05. 
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Aberrant signaling pathways during differentiation of SIRT1
-/-
 ESCs 
Activation of the Ras-Raf-Mek-Erk signaling cascade is important for morphological and 
gene expression changes indicative of early ES cell differentiation by LIF withdrawal 
(Lee, McCool et al. 2006). When the Erk pathway is inhibited in LIF withdrawn cells, the 
pluripotent marker Oct4 shows delayed down-regulation (Lee, McCool et al. 2006). 
SIRT1 inhibition reduces Erk1/2 signaling in cultured neurons (Li, Xu et al. 2008), so we 
assessed whether delay in loss of pluripotency markers in SIRT1
-/-
 EBs is associated with 
effects on the Erk pathway during SIRT1
-/-
 ES cell commitment. Phosphorylated Erk1/2 
was gradually increased during early SIRT1
+/+ 
ES cell differentiation, consistent with a 
previous report (Lee, McCool et al. 2006). However, Erk phosphorylation was greatly 
impaired in SIRT1
-/-
 cells (Figure 20A, B). Bone morphogenetic protein (BMP), 
fibroblast growth factor (FGF) and Wnt pathways are there major pathways involved in 
mesoderm commitment and development. To evaluate signaling pathways for 
mesodermal differentiation within EBs, high-throughput mRNA expression profiling was 
used to examine gene expression involved in bone morphogenetic protein (BMP), 
fibroblast growth factor (FGF) and Wnt pathways. Expression of Bmpr, smad8, and 
smad3 was delayed in SIRT1
-/-
 compared with WT
 
EBs. Smads are intracellular signal 
transducers of the BMP pathway. Among them, Smad7 is an inhibitory molecule for the 
BMP-SMAD pathway (Casellas and Brivanlou 1998). Smad7 inhibits mesoderm 
formation and promotes neural cell fate in Xenopus embryos (Bhushan, Chen et al. 1998). 
Of note, Smad7 was persistently expressed at higher levels in SIRT1
-/-
 than in WT 
 
EBs 
(Figure 21). This is interesting in light of Smad7 down-regulation by SIRT1 (Kume, 
Haneda et al. 2007). Expression of several components of FGF and Wnt signal 
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transduction pathways were altered in SIRT1
-/-
 EBs (Figure 22A, B). FGF and Wnt 
pathways are implicated in hematopoietic development through protein network 
interactions (Huelsken and Birchmeier 2001; Thisse and Thisse 2005), suggesting that 
SIRT1 deficiency may impair embryonic hematopoiesis indirectly through broad signal 
transduction networks. Our gene-array expression analysis indicates a role for SIRT1 in 
intracellular signaling during hematopoietic cell development. 
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Figure 20 
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Figure 20: Western Blot analysis of Erk signaling pathways.  
WT and SIRT1
-/- 
EBs were collected at days 0, 12hr, 1, 2, and 3 upon ES cell 
differentiation. Cellular lysates were taken and western blot were performed for protein 
levels. (A) Representative blot and (B) quantification showing phosphorylation of Erk, 
and Erk1/2 protein expression at different time points during EB development. Data are 
shown as mean ± SEM. N=3; *, p<0.05. 
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Figure 21 
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Figure 21: qRT-PCR analysis of mRNA levels of genes (BMPr2, Smad8, Smad3 and 
Smad7) involved in BMP pathways in day 0-10 WT and SIRT1
-/-
 EBs.  
D0 represents undifferentiated ES cells. Graphs were plotted in logarithmic scale. Data 
are relative to WT D0 control and mRNA levels of each gene were compared between 
WT and SIRT1
-/- 
EBs at each time point. Results were of three independent experiments 
performed in triplicate. *, p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
107 
 
Figure 22 
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Figure 22: (A) qRT-PCR analysis of mRNA levels of genes (Lef1, Tcf7, Ctnnb1 amd 
Gsk3b) involved in Wnt pathways in day 0-10 WT and SIRT1
-/-
 EBs. (B) qRT-PCR 
analysis of mRNA levels of genes (Fgfr1, Raf1, Mapk8 and Mapk14) involved in FGF 
pathways in day 0-10 WT and SIRT1
-/-
 EBs. Graphs were plotted in logarithmic scale. 
Data are relative to WT D0 control and mRNA levels of each gene were compared 
between WT and SIRT1
-/-
 EBs at each time point. Results were the average of three 
independent experiments, each performed in triplicate. *, p<0.05. 
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Reintroduction of SIRT1 gene into SIRT1
-/-
 ESCs rescues  normal hematopoietic 
phenotype of SIRT1
-/-
 EBs 
To examine whether the abnormal differentiation phenotype of SIRT1
-/-
 cells can be 
corrected by adding back a wild-type SIRT1 gene, in vitro gene reconstitution studies 
were performed. Lentiviral vectors were constructed containing EGFP IRES or the 
SIRT1 gene under control of a Ubc promoter (Figure 23A), giving levels of SIRT1 gene 
expression proportional to GFP fluorescence intensity. Vector containing EGFP gene 
alone was used as a control. ES cells were efficiently infected, as shown by flow 
cytometry 48 hours after infection (Figure 23B). ES cells with high level expression of 
GFP were sorted and analyzed for SIRT1 expression. Western blot analysis demonstrated 
that SIRT1 was expressed in SIRT1
-/-
 cells transfected with the SIRT1 vector (Figure 
23B). SIRT1
-/-
 cells generated few EryP on day 4.5, but numbers of primitive progenitors 
in SIRT1
-/-
 cells was significantly increased with reconstitution of SIRT1 to a level 
comparable to WT
 
cells (Figure 24A). Also, expression of hemoglobin genes, Hbb-bh1 
(Figure 24B) and Hbb-b1 (Figure 24C) was recovered in SIRT1
-/-
 cells with the SIRT1 
gene insert vector, compared with WT
 
cells. This demonstrates that the altered 
hematopoietic differentiation potential observed for SIRT1
-/-
 cells was specific to deletion 
of SIRT1. 
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Figure 23 
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Figure 23: Ectopic expression of exogenous SIRT1 in SIRT1
-/-
 ES cells.  
(A) Diagram of pLenti6-SIRT1-Venus lentiviral vector. (B) Transfected SIRT1
-/-
 ES cells 
were sorted and expression of SIRT1 protein was determined by western blotting. 
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Figure 24 
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Figure 24: Reconstitution of SIRT1 in SIRT1
-/-
 mES cells rescued the differentiation 
of primitive erythroid progenitors. 
 (A) Number of primitive erythroid colonies generated by day 4.5 and day 5 WT 
(SIRT1
+/+
), SIRT1
-/-
 + null, and SIRT1
-/-
 + SIRT1 ES cells. (B, C) qRT-PCR analysis of 
mRNA levels of embryonic globin (Hbb-bh1) and adult globin (Hbb-b1) in Day (D) 0-8 
WT (SIRT1
+/+
), SIRT1
-/-
 + null, and SIRT1
-/-
 + SIRT1 EBs. Data represent fold changes in 
EBs, relative to SIRT1
+/+
 D0 control and comparison between WT (SIRT1
+/+
), SIRT1
-/-
 + 
null, and SIRT1
-/-
 + SIRT1 EBs at each time point. Results are average of three 
independent experiments. Each data point denotes six biological replicates; *, p<0.05; **, 
p<0.01; ***, p<0.001. Data are shown as mean ± SEM. 
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Part II: SIRT1 deficiency compromises embryonic and adult hematopoiesis in the 
mouse 
Defective primitive hematopoiesis during early development and decreased adult 
hematopoiesis in SIRT1
-/-
 mice 
 
Based on our above studies we evaluated embryo and adult bone marrow hematopoiesis 
in SIRT1
+/+
, SIRT1
+/- 
and SIRT1
-/- 
mice (Wang, Sengupta et al. 2008). We performed in 
vitro colony-forming assays on yolk sac cells from E8 to E8.25 embryos. We observed 
significant decreases in absolute numbers of primitive erythroid progenitors from SIRT1
-/-
, 
but not SIRT1
+/-
, E8 to E8.25 yolk sacs under normoxic conditions compared to SIRT1 
+/+
 
yolk sacs (Figure 25A). Genotypes of the yolk sacs (Figure 25B) were confirmed and the 
targeting vectors for deletion of SIRT1 were listed in Figure 25C. Less than 10% of 
SIRT1
-/-
 mice survive to birth (Wang, Sengupta et al. 2008), but SIRT1
+/-
 mice are born 
with normal Mendelian genetics. We assessed absolute numbers of hematopoietic 
progenitor cells (CFU-GM, BFU-E, and CFU-GEMM) per femur of 5 week old SIRT1
+/- 
vs. SIRT1
+/+
 mice detected via culturing bone marrow cells in vitro at both ~20% and 5% 
O2 tension. In that way, we could determine if there were differences in progenitor cell 
numbers in SIRT1
+/-
 and SIRT1
+/+
 cells, and whether or not the growth of these cells 
could be enhanced by growth in lowered O2. While we detected no significant differences 
in colony numbers of SIRT1
+/+
 and SIRT1
+/-
 cells grown in vitro under normoxic 
conditions from bone marrow of 5 week old mice, we found that SIRT1
+/+
, but not 
SIRT1
+/-
 cells were enhanced in numbers at lowered O2 (Figure 26). Thus, SIRT1
+/-
 cells 
do not sense enhanced growth conditions of lowered O2. We were also able to evaluate 
SIRT1
+/+
, SIRT1+/- and SIRT1
-/-
 mice that were over one year old.  As shown in Figure 
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27A, absolute numbers of SIRT1
+/-
 and SIRT1
-/-
 progenitors were significantly decreased 
by almost half when cells were cultured under normoxic conditions, suggesting an age-
related decrease in SIRT
+/-
 numbers. Consistent with the SIRT1
+/-
 data from 5 week old 
mice (Figure 26), neither SIRT1
+/-
 nor SIRT1
-/-
 progenitors from the more aged mice 
responded to the enhancing effects of lowered O2 that the SIRT1
+/+
 cells responded to, 
confirming that SIRT1
+/-
, and also SIRT1
-/-
 progenitors from adult bone marrow fail to 
respond to lowered O2. At lowered O2, the differences detected in numbers of progenitor 
cells in S-phase from SIRT1
+/+
 mice to that of either SIRT1
+/-
 or SIRT1
-/-
, was 
substantially greater than that seen at normoxia (Figure 27B). Nucleated bone marrow 
cellularities/femur did not show significant differences between SIRT1
+/+
, SIRT1
+/-
, or 
SIRT1
-/-
 mice (Table 3). We also assessed the in vitro survival of hematopoietic 
progenitor cells (CFU-GM) from 5 week and over 1 year old mice growing at 5% O2 in 
response to growth factor deprivation and delayed addition of Epo, PWMSCM and TPO 
at day 1 after culture in the presence of FBS.  Seven days after addition of cytokines there 
was a significantly greater decrease in colony formation for 5 week old bone marrow of 
SIRT1
+/-
 mice and SIRT1
-/-
 marrow of >1 year old mice compared to their comparable 
aged matched SIRT1
+/+
 mice (Figure 28). This demonstrates that SIRT1
+/-
 and SIRT1
-/- 
progenitors survive less well than the SIRT1
+/+
 progenitors, under these conditions of 
growth factor deprivation. Also, there was a significantly greater decrease in progenitor 
cells from older compared to younger SIRT1
+/+
 mice.  
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Figure 25 
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Figure 25: Hematopoietic progenitor cell colony forming assay from yolk sac of WT 
(SIRT1
+/+
), SIRT1
+/- 
and SIRT1
-/- 
mice.  
(A) Primitive erythroid colony formation from yolk sac cells generated from E8 to E8.25 
SIRT1
+/+
, SIRT
+/-
 and SIRT1
-/- 
embryos (SIRT1
+/+
, n=11; heterozygous, n=10; SIRT1
-/-
, 
n=4) were grown in methylcellulose-based medium. Data are shown as mean ± SD; *, 
p<0.01. (B) PCR shows the genotyping of SIRT1 mutant embryos. The primers are: 
forward-5‟-TCCTTGCCACAGTCACTCAC-3‟, reverse for wild type 5‟-
CATCTAAACTTTGTTGGCTGC-3‟, reverse for deletion 5‟-ACAGTCCCATTCCCAT 
ACC-3‟. Primers 1 and 3 are located within intron4 and amplify the WT allele (600bp). 
Primer 2 located within exon7, the combination of primer1 and 2 amplifies the deleted 
allele (716bp). (C) Targeted disruption of SIRT1 in mouse. Figure C is adapted from 
(Wang, Sengupta et al. 2008). 
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Figure 26 
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Figure 26: Hematopoietic progenitor cell colony formation from bone marrow of 5 week 
old SIRT1 heterozygote (SIRT1
+/-
) or WT controls under normoxia (20%O2) and 5% O2 
conditions. Data are shown as mean ± SD; ND=SIRT1
-/-
 cells were not available for use 
and were not done. Data are the average of 3-5 mice/group. Numbers of HPC colonies 
were compared between WT mice under normoxia and 5% O2 and WT and SIRT1+/- 
mice under normoxia and 5% O2. P values for each group comparison were notified in 
the figure. 
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Figure 27 
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Figure 27: (A) Hematopoietic progenitor cell colony formation from bone marrow of 12 
month old SIRT1 heterozygote (SIRT1
+/-
) or homozygote (SIRT1
-/-
) null mice or from 
WT controls under normoxia (20%O2) or 5% O2 conditions. (B) Cycling status of mouse 
bone marrow progenitor cells generated from 12 months old WT (SIRT1
+/+
), SIRT1
+/-
 and 
SIRT1
-/-
 mice under normoxia (20%O2) and 5% O2 conditions. This shows percent 
progenitors in DNA synthesis (S-phase) as determined by high specific activity tritiated 
thymidine kill technique (Broxmeyer, Orschell et al. 2005). P values were calculated with 
Student‟s t test. ND= not done. Data are the average of 3-5 mice/group. 
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Figure 28 
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Figure 28: Survival of hematopoietic progenitor cells in vitro from bone marrow of 5 
week old SIRT1 heterozygote (SIRT1
+/-
) or WT controls (SIRT1
+/+
), and from bone 
marrow of 12 month old homozygote (SIRT1
-/-
) null mice or from WT controls (SIRT1
+/+
) 
after 1 day delayed addition of cytokines as denoted by decreased colony formation. 
Results are expressed as mean ±ISEM for 4-5 mice per group.  
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 NUCLEATED CELLULARITY (BONE MARROW) 
 5 WEEKS OLD >12 MONTHS 
  MEAN          SEM             P MEAN             SEM           P 
WT (+/+)   15.4      1.0 CONTROL  20.4        2.4 CONTROL 
HET(+/-)   15.3      3.0    0.490 14.4        4.4    0.230 
 KO (-/-)    ND      ND      ND 15.1        2.7    0.105 
Table 3: Nucleated bone marrow cellularity of WT, SRIT1
+/-
 and SIRT1
-/-
 mice 
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Table 3: Nucleated cellularity/femur for WT, SIRT1
+/+
 and SIRT1
-/-
 mice of 5 weeks and 
over a year old. ND=not done. Data are the average of 3-5 mice/group. 
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DISCUSSION 
Although roles of SIRT1 in cell differentiation, self-renewal and corresponding signal 
transduction pathways have been investigated previously in different cell types, roles of 
SIRT1 during ES cell differentiation commitment and for ES cell self-renewal are poorly 
understood. In this study, using an ES cell/EB in vitro differentiation system, our results 
demonstrated that loss of SIRT1 delayed the timing of ES cells to exit the pluripotent 
stem cell program upon LIF withdrawal, and SIRT1 deficiency compromises 
hematopoietic lineage differentiation of mouse ES cells, while SIRT1 is dispensable for 
self-renewal of ES cells.  
With regard to differentiation, SIRT1 has been shown to regulate skeletal muscle gene 
expression and differentiation as a potential sensor of the redox state (Fulco, Schiltz et al. 
2003). SIRT1 forms a complex with the acetyltransferase PCAF and MyoD and, when 
overexpressed, retards muscle differentiation. Conversely, cells with decreased SIRT1 
differentiate prematurely (Fulco, Schiltz et al. 2003). SIRT1 also regulates cell 
differentiation in pig preadipocytes and normal human keratinocytes (Bai, Pang et al. 
2008; Blander, Bhimavarapu et al. 2009). SIRT1 mRNA was widely expressed in various 
pig tissues from different developmental stages and throughout the entire differentiation 
process of pig preadipocytes. Resveratrol (SIRT1 activator) significantly inhibited pig 
preadipocyte proliferation and differentiation, while nicotinamide (SIRT1 inhibitor) 
greatly stimulated the proliferation and differentiation of pig preadipocytes (Bai, Pang et 
al. 2008). In keratinocytes, nicotinamide inhibited expression of keratinocyte 
differentiation markers, whereas resveratrol enhanced expression of keratinocyte 
differentiation markers. Similar results were obtained in keratinocytes manipulated to 
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overexpress or underexpress SIRT1 (Blander, Bhimavarapu et al. 2009). Most notably, 
under oxidative conditions, SIRT1 participates in suppression of neurogenesis. Direct 
activation of SIRT1 suppressed proliferation of nuclear progenitor cells (NPCs), whereas 
reducing conditions had the opposite effect (Prozorovski, Schulze-Topphoff et al. 2008). 
In contrast, under normal conditions, overexpression of SIRT1 enhances neuronal 
differentiation. The number of neurospheres was significantly decreased by 
pharmacological inhibitors of SIRT1, dominant-negative SIRT1 and SIRT1-siRNA, 
whereas overexpression of SIRT1 enhanced neuronal differentiation and decreased Hes1 
expression (Hisahara, Chiba et al. 2008; Prozorovski, Schulze-Topphoff et al. 2008). 
Based on these previous reports, it is possible that a role for SIRT1 in promoting or 
suppressing differentiation may be condition-related and cell-type specific.  
In our study, SIRT1
-/- 
ES cells did not show marked differences in morphology and 
expression of mES-specific markers compared to WT R1 mES cells (Figure 6A, B), 
suggesting that SIRT1 is dispensable for maintain pluripotency of mES cells. We recently 
reported that under oxidative stress, in the absence of 2-ME, SIRT1 is important for 
maintenance of ESCs by inhibiting p53-mediated suppression of Nanog expression (Han, 
Song et al. 2008). However, in this present study with LIF-withdrawal and in the 
presence of 2-ME, SIRT1 clearly plays a role in differentiation from mesoderm to 
specific hematopoietic lineage commitment. We compared the expression of acetylated-
p53 upon ES cell differentiation between WT and SIRT1
-/-
 cells with LIF-withdrawal and 
in the presence of 2-ME. However, we did not find significant difference of expression of 
acetylated-p53 between WT and SIRT1
-/-
 ES cells (data not shown), demonstrating that 
SIRT1 is a condition-sensitive protein and might play distinct roles on differentiation 
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under specific conditions via different pathways. Recently, Calvanese et al. (Calvanese, 
Lara et al. 2010) published that elimination of SIRT1 in mouse TC1 ES cells has little 
impact on expression of pluripotency factors and SIRT1 regulation of developmental 
genes during differentiation of mouse and human ES cells. The impact of SIRT1 
silencing on the expression of pluripotency and differentiation markers are much greater 
after induction of differentiation, which is consistent with our work that SIRT1 is 
dispensable for self-renewal of ES cells, but regulates the genes involved in 
differentiation.  
Although functional requirements for SIRT1 during embryogenesis and gametogenesis 
have been demonstrated in mammals (McBurney, Yang et al. 2003), roles for SIRT1 
during ES cell differentiation commitment are poorly understood. In this study, using an 
ES cell/EB in vitro differentiation system, we demonstrate that loss of SIRT1 affects the 
potential and timing of ES cells to exit the pluripotent stem cell program upon LIF 
withdrawal. The most apparent defect identified is likely delayed shut off of Oct4 and 
Nanog (Figure 17A) and persistent Fgf5 (Figure 17B) expression, which could account 
for diminished mesoderm commitment. Inactivation of Oct4 occurs concomitantly with 
deacetylation of its promoter region shortly after differentiation begins (Feldman, Gerson 
et al. 2006) and the level of Nanog decreases rapidly following LIF withdrawal (Torres 
and Watt 2008). Upon removal of LIF or induction of differentiation by addition of 
external signals, SIRT1
+/+ 
ES cells are able to rapidly down-regulate these genes in 
response to external signals. However, as demonstrated herein, the ability to switch off 
Oct4 and Nanog expression is delayed by loss of SIRT1. Early differentiation of ES cells 
into primitive ectoderm, key to formation of the three germ layers, was unaffected, as 
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suggested by the presence of Oct4 and Fgf5 expression in day 2 EBs. However, SIRT1
-/-
 
EBs persistently express high levels of Fgf5 from day 6 to 10. Further analysis of EB 
transcriptional profiles indicates delayed and sustained expression of specific mesoderm 
markers (T and Wnt3) in SIRT1
-/-
 EBs. The delayed/sustained Fgf5/T/Wnt3 (Figure 17B) 
gene expression supports functional data regarding delays/defects of development of BL-
CFCs and generation of Flk-1
+
 c-Kit
- 
cells in SIRT1
-/-
 EBs. SIRT1
-/-
 ES cells did not show 
marked differences in morphology and expression of mES-specific markers, indicating 
that in unperturbed conditions, SIRT1 is not required to maintain the undifferentiated 
phenotype state. This is consistent with previous findings (McBurney, Yang et al. 2003) 
and studies suggesting that elimination of SIRT1 in mouse TC1 ES cells has little impact 
on expression of pluripotency factors (Calvanese, Lara et al. 2010). However, our present 
study, in light of the latter work indicating SIRT1 regulation of developmental genes 
during differentiation of mouse and human ES cells, strongly suggests that SIRT1 
depletion most dramatically affected target gene expression profiles during early stage ES 
cell commitment to differentiation.  
Our results also suggest that SIRT1 deficiency impairs proper differentiation of blast cell 
colonies, the hematopoietic developmental potential of blast cells in vitro, and to a lesser 
extent of endothelial cells where primitive vascular network formation is impaired. 
Hematopoietic progenitor differentiation of SIRT1
-/-
cells is defective. Low level mRNA 
expression of genes associated with hematopoietic development such as Scl, β-H1 globin 
and β-major globin was detected at days 4, 6, 8 in SIRT1-/- EBs (Figure 17B), consistent 
with the early defect in primitive and definitive hematopoiesis. Basic helix-loop-helix 
transcription factor Scl is necessary for the early stages of in vitro differentiation of 
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mesoderm to hematopoietic lineages and acts during a limited time window (D'Souza, 
Elefanty et al. 2005). Scl
-/-
 ES cells were not able to form blast colonies, but did form 
transitional colonies (Robertson, Kennedy et al. 2000). Transitional colonies derived 
from Scl
-/- 
ES cells are unable to generate hematopoietic precursors but do form cells with 
endothelial characteristics (Robertson, Kennedy et al. 2000). Induction of Scl at later than 
day 4 could not restore competence to differentiate to hematopoietic progenitor cell fate 
(D'Souza, Elefanty et al. 2005). Mesodermal cells that failed to express Scl at the right 
stage appear to be irreversibly excluded from a hematopoietic progenitor fate. In our 
study, we found that SIRT1
-/-
 EBs has the same phenotype as Scl
-/-
 EBs. SIRT1
-/-
 ES cells 
generated a greater number of transitional colonies instead of blast colonies. SIRT1
-/-
 ES 
cells were able to form endothelial lineages, but were defective in formation of a full 
vascular-like network. The progression of hematopoiesis of blast cells was defective in 
SIRT1
-/-
 EBs. Thus, decreased expression of Scl, combined with sustained expression of 
Fgf5/T, at the mesoderm stage in SIRT1
-/-
 EBs may explain its inability to adequately 
generate mature blast colonies and progress into primitive hematopoietic commitment. In 
addition, the transitional colonies formed during SIRT1
-/-
 BL-CFC culture system had the 
similar morphology as those formed from Scl
-/-
 EBs. Whether the defect in the formation 
of mature blast colonies from SIRT1
-/-
 ES cells would be rescued by the reconstitution of 
Scl at the early time points and whether SIRT1 regulates Scl directly at the post-
translational level or indirectly at the transcription level will be an interesting avenue of 
further study.  
ES cell pluripotency and cell fate determination are profoundly affected by MAPK, BMP, 
FGF and Wnt signaling pathways (Loebel, Watson et al. 2003). Ras/Erk pathway 
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promotes differentiation of and suppresses self-renewal of mouse ES cells. Lee et al. 
showed that when the Erk pathway is inhibited in LIF withdrawn cells, the pluripotent 
marker Oct4 shows delayed downregulation (Lee, McCool et al. 2006). As shown in 
Figure 17A, pluripotent markers Oct and Nanog both showed delayed down-regulation in 
SIRT1
-/-
 EBs. Phosphorylated Erk1/2 was gradually increased during WT ES cell 
differentiation, consistent with previous report (Lee, McCool et al. 2006). As noted, 
phosphorylation of Erk is less activated in SIRT1
-/-
 cells. The delayed down-regulation of 
Oct4 and Nanog in SIRT1
-/- 
cells can be explained by the aberrant Erk signaling pathways. 
Taken together, we proposed a mole for SIRT1-mediated regulation of hematopoietic 
differentiation of mESCs as shown in Figure 29. In our model, the hemangioblast was 
listed as the progenitor give rise to an intermediate-hemogenic endothelium and further 
differentiate into both hematopoiesis and vasculogenesis. Recent studies provided 
evidence for the clonal origin of hematopoietic cells from a single hemogenic endothelial 
cell in vitro and for the generation of hematopoietic stem cells from hemogenic 
endothelium in vivo directly, which challenged the old concept of the hemangioblast and 
existence of the hemangioblast in vivo (Boisset, van Cappellen et al. 2010; Lancrin, 
Sroczynska et al. 2010; Swiers, Speck et al. 2010). However, this study result has been 
refuted by a recent study demonstrating that the existence of a population of 
hemangioblasts in the adult mouse uterus, adding substance to the long-lasting debate on 
the persistence of these ancestral progenitor cells in the developed organism (Peault 2010; 
Sun, Zhang et al. 2010). These intriguing observations revive a continuing debate and 
should stimulate further experimentation to confirm and document the presence of 
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hemangioblast and angio-hematopoietic stem cells, therefore understanding how blood 
cells are generated. 
The formation of blood in the blood in the embryo is dependent on BMP. In Xenopus, 
formation of primitive and definitive blood requires BMP signaling (Walmsley, Ciau-
Uitz et al. 2002). BMPs promote blood formation by specifying mesoderm during early 
dorsoventral (DV) formation. BMP induction during early gastrulation causes excess 
ventral-posterior (V-P) mesoderm and enhanced hematopoiesis. Moreover, specific 
involvement of the BMP signaling transducers Smad1, Smad5 and Smad7 has been 
demonstrated in blood development (Lengerke, Schmitt et al. 2008). The inhibitory Smad 
for BMP signaling, Smad7, is involved in early patterning events. Low levels of Smad7 
block activation of dorsal mesoderm genes, and high levels block all mesoderm gene 
expression in Xenopus embryos (Bhushan, Chen et al. 1998). Kume et al. showed that in 
mesangial cells, SIRT1 directly interacts with the N-terminus of Smad 7. Furthermore, 
SIRT1 reversed acetyl-transferase (p300) mediated acetylation of two lysine residues 
(Lys-64 and 70) on Smad7. The Smad7 expression level was increased by SIRT1 knock-
down and reduced by SIRT1 overexpression. SIRT1-mediated deacetylation of Smad7 
enhanced Smad ubiquitination regulatory factor 1 (Smurf1) mediated ubiquitin 
proteasome degradation, which contributed to the low expression of Smad7 in SIRT1 
overexpression mesangial cells. (Kume, Haneda et al. 2007). We found by qRT-PCR, 
that Smad7 is persistently expressed in SIRT1
-/-
 EBs. This persistence may account for 
defective hematopoietic differentiation in SIRT1
-/-
 EBs. Based on the above study in 
mesangial cells, it will be interesting to explore further whether SIRT1 interacts with 
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Smad7 at the protein level and reverses acetyl-transferase (p300) mediated acetylation of 
two lysine residues (Lys-64 and 70) on Smad7 in ES cells. 
Evidence from mouse models indicates that SIRT1 is a central regulator of embryonic 
and somatic stem cell function (Han, Song et al. 2008; Prozorovski, Schulze-Topphoff et 
al. 2008). We found that lack of SIRT1 expression led to decreases in primitive erythroid 
progenitor cells in E8 to E8.25 yolk sacs. Since the majority of SIRT1 null embryos die 
between E9.5 and E14.5, we did not have access to SIRT1
-/-
 embryos at later time points. 
There is ample evidence that SIRT1
-/-
 mice have developmental defects such as markedly 
smaller size as compared to their littermates and slower development. We cannot exclude 
the possibility the decrease in Ery-P is due to a developmental delay in SIRT1
-/- 
embryos.  
Consistent with studies of Wang et al. (Wang, Sengupta et al. 2008), SIRT1
-/-
 embryos 
were abnormally small. In addition, these embryos show nuclear fragmentation and cell 
death. We also found that hematopoietic progenitor cells from SIRT1
+/+
 and SIRT1
-/-
 mice 
survive less well in vitro at lowered O2 tension after the stress of delayed addition of 
growth factors.  Decreased survival is directly associated with enhanced apoptosis 
(Broxmeyer, Cooper et al. 2003). This could be another reason for differences in numbers 
of Ery-P in SIRT1
-/- 
embryos. Analysis of bone marrow of SIRT1
-/- 
adult mice 
demonstrated decreased hematopoietic progenitor cell numbers and cell cycle status. The 
decrease was more apparent when cells were cultured under lowered O2 tension. This is 
of interest since during hypoxia, activated SIRT1 augments hypoxia-inducible factor 2 
alpha (HIF-2α) signaling and consequently participates in regulation of the HIF-2α target 
gene, Epo (Dioum, Chen et al. 2009). Congenital SIRT1 deficiency affects fetal and adult 
Epo gene expression in mice (Dioum, Chen et al. 2009). Epo, generally considered an 
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erythropoietic growth factor, is also a potent prosurvival factor that protects developing 
stem and progenitor cells in a variety of organs (Noguchi, Asavaritikrai et al. 2007). It 
would be very interesting to explore further whether SIRT1, HIF-2α and Epo signaling 
would be associated with the defective phenotype of SIRT1
-/-
 mice we demonstrated. 
Renal Epo gene expression differs between SIRT1
+/-
 and SIRT1
+/+
 mice exposed to 6% 
O2, while both groups of mice have similar amounts of renal Epo mRNA under ambient 
O2 (Dioum, Chen et al. 2009). Similarly, our data showed that hematopoietic progenitor 
colony formation from adult mice significantly differed between SIRT1
+/+ 
and SIRT1
+/-
 
mice under 5% O2 while both groups of mice had similar numbers under normoxia.  
Sirtuins are implicated in aging (Donmez and Guarente 2010). SIRT1
+/-
 mice are born 
with apparently normal mendelian frequency, while less than 10% of SIRT1
-/-
 mice live to 
birth. It is not yet clear why some SIRT1
-/-
 mice live to birth while others don‟t. We 
detected no significant differences in primitive erythroid progenitors generated between 
SIRT1
+/-
 and SIRT1
-/-
 embryos, similar to HPC numbers from 5 week old SIRT1
+/-
 and 
SIRT1
+/+
 mice when cells were cultured under normoxia. That SIRT1
+/-
 cells from adult 
mice (>12 months) demonstrate decreased hematopoietic progenitor cell numbers at 
normoxia, similar to that of SIRT1
-/-
 cells and that SIRT1
+/-
 and SIRT1
-/-
 cells in the aged 
mice show even greater differences compared with SIRT1
+/+ 
mice when cells are cultured 
at lowered O2 allows us to evaluate a role for SIRT1 in the hematopoietic aging process, 
as there will be more SIRT1
+/-
 than SIRT1
-/-
 mice surviving to older ages. 
Analyses of SIRT1
-/-
 mice revealed that this protein serves essential functions during 
embryonic and postnatal development, as well as for several homeostatic programs 
during adulthood (Cheng, Mostoslavsky et al. 2003; McBurney, Yang et al. 2003; 
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Coussens, Maresh et al. 2008; Narala, Allsopp et al. 2008). Our results demonstrate that 
SIRT1 is an important regulator of mES cell differentiation and hematopoiesis, and 
suggest its role in the earliest stages of hematopoietic and endothelial development. Since 
hematopoietic and endothelial development is not extinguished by knock-out of SIRT1, 
and definitive hematopoiesis is less affected compared with primitive hematopoiesis, 
there might be distinct pathways of differentiation for primitive and definitive 
hematopoiesis, or compensation by other sirtuin, or non-sirtuin family members. 
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Figure 29 
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Figure 29: Proposed model for SIRT1–mediated regulation of hematopoietic 
differentiation of mES cells.  
Upon removal of LIF or induction of differentiation by addition of external signals, WT
 
ES cells are able to rapidly upregulate of phosphorylation of Erk1/2 and downregulate the 
expression of Oct4 and Nanog in response to external signals. Next, Fgf5, a gene 
expressed in the epiblast of early embryos, down-regulated after pre-hemangioblast 
mesoderm stage in WT ES cells. Then T, Wnt3 and Scl were upregulated for mesoderm 
commitment and progression into hematopoietic differentiation of WT ES cells. However, 
in SIRT1-/- ES cells, the ability to switch off Oct4 and Nanog expression and activation 
of Erk pathway is delayed by loss of SIRT1. SIRT1
-/-
 EBs persistently express high levels 
of Fgf5 from day 6 to 10. The delayed/sustained Fgf5/T/Wnt3 gene expression and 
decreased Scl expression supports functional data regarding delays/defects of 
development of BL-CFCs, generation of Flk-1
+
/c-Kit
- 
cells in SIRT1
-/-
 EBs, and 
generation of primitive and definitive hematopoietic progenitor cells. 
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FUTURE DIRECTIONS 
 
Testing SIRT1 activators and inhibitors in mES cell hematopoietic differentiation 
As discussed in the Introduction and stated in the Discussion, SIRT1 activators and 
inhibitors have been investigated extensively and reported to modulate a variety of 
processes in mammals in a SIRT1-dependent manner such as differentiation, tumor 
suppression and inflammation (Picard, Kurtev et al. 2004; Yeung, Hoberg et al. 2004; 
Parker, Arango et al. 2005). We hypothesize that the SIRT1 activator (resveratrol) 
promotes hematopoietic differentiation of mES cells, while SIRT1 inhibitors (NAM, 
Sirtinol) compromise hematopoietic differentiation of mES cells, resulting in the 
phenotype similar to SIRT1
-/-
 mES cells. To test this, first we will determine the optimal 
concentration of resveratrol/NAM/Sirtinol. We will further evaluate the formation of 
blast colony, primitive progenitor cells, and definitive progenitor cells derived from mES 
cells treated with resveratrol/NAM/Sirtinol by in vitro/in vivo hematopoietic 
differentiation assay compared WT ES cells without treatment. We would expect that 
treatment with resveratrol increases the formation of blast colonies and primitive and 
definitive progenitor cells. However, treatment with inhibitors of SIRT1 perturbs the 
formation of those progenitor cells. 
SIRT1 localization in mES cells 
SIRT1 modulates neuronal differentiation through its nuclear translocation. SIRT1 was 
found in the cytoplasm of embryonic and adult NPCs. However, in response to 
differentiation stimulus, SIRT1 was transiently localized in the nucleus (Hisahara, Chiba 
et al. 2008). Furthermore, to explore further how SIRT1 regulates mES cell 
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differentiation, we could investigate its localization in mES cells and after cell 
differentiation by immunostaining. We can also determine its subcellular distribution by 
western blot analysis of cytoplasmic and nuclear fraction of cells under un-differentiation 
or differentiation conditions.  
SIRT1 regulation of Scl in mES cells 
As we stated in the Discussion, decreased expression of Scl at the mesoderm stage in 
SIRT1
-/-
 EBs may explain its inability to adequately generate mature blast colonies and 
progress into primitive hematopoietic commitment. In addition, the transitional colonies 
formed during SIRT1
-/-
 BL-CFC culture system had a similar morphology to those 
formed from Scl
-/-
 EBs. To further explore the relationship between Scl and SIRT1, we 
can determine whether the defect in the formation of mature blast colonies from SIRT1
-/-
 
ES cells would be rescued by the reconstitution of Scl at the early time points. SIRT1
-/-
 
ES cells will be transfected with a lentiviral vector overexpressing Scl and then 
performed in vitro blast-colony forming cell assay upon SIRT1
-/-
 ES cells. We would 
expect the increase of mature blast colony formation and the appropriate progression into 
hematopoietic lineage. 
SIRT1 regulation on Smad7 in mES cells 
By qRT-PCR we found that Smad7 is persistently expressed in SIRT1
-/-
 EBs. Persistent 
expression of Smad7 in SIRT1
-/- 
EBs may account for defective hematopoietic 
differentiation in SIRT1
-/-
 EBs. Therefore, it will be interesting to determine whether 
SIRT1 interacts with Smad7 at the protein level in mES cells under undifferentiated or 
differentiated conditions. To investigate the interaction between SIRT1 and Smad7, we 
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can perform co-immunoprecipitation (IP) analysis. We can also determine which part of 
Smad7 interacts with SIRT1 by using deletion mutants of Smad7 vectors, Smad7 (WT), 
Smad7 (ΔCT), and Smad7 (ΔNT). We can further explore whether SIRT1 deacetylates 
the lysine residues of Smad7 based on SIRT1 is a deacetylase. 
SIRT1 regulation of survivin in endothelial differentiation of mES cells 
Our results showed that vascular sprout formation developed from day 6 WT
 
and SIRT1
-/-
 
EBs developed similar endothelial outgrowths when embedded into collagen gel (Figure 
15A). However, SIRT1
-/-
 cells did not form a full vascular-like network in vitro (Figure 
16A); they had significantly fewer class III (many sprouts but not network) and class IV 
(abundant networked tubules) vascular sprout formations than WT
 
EBs (Figure 16B). 
Survivin plays a key role in maintenance of vascular integrity and is crucial for normal 
embryonic angiogenesis (Zwerts, Lupu et al. 2007). It has been shown that SIRT1 
interacts with survivin by deacetylating H3K9 within the promoter of survivin (Wang, 
Zheng et al. 2008; Deng 2009). We hypothesize that the role of SIRT1 during vascular 
growth and maturation derived from mES cells could be mediated, at least in part, by a 
deacetylation-dependent regulation of survivin. To test whether SIRT1 could regulate 
survivin acetylation in endothelial cells, we will perform coimmunoprecipitation 
experiments in human umbilical vein endothelial cells transfected with Myc-tagged 
SIRT1 and Flag-tagged survivin. We would expect to detect an interaction between 
SIRT1 and survivin when immunoprecipitation is performed with either an anti-Flag or 
anti-Myc antibody. We will next test the possibility that SIRT1 might interact with 
survivin to regulate its deacetylation. In order to address whether SIRT1-mediated 
regulation of survivin is capable of regulating the angiogenic activity of survivin, we will 
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transfect endothelial cells with siRNAs targeting SIRT1 and survivin, and will assess the 
sprout-forming activity of the transfected cells in a spheroid assay. We would expect 
silencing of survivin gene expression lead to decreased basal angiogenic activity. If 
surviving is overexpressed, it might partially rescue the inhibitory effects of SIRT1 gene 
silencing on the sprout-forming activity of endothelial cells, which would suggest that 
SIRT1 regulates endothelial angiogenic functions, at least in part, by modulating the 
transcriptional activity of survivin. 
SIRT1 regulation on HIF-2α signaling in mES cells under hypoxia 
Hypoxia changes cellular metabolism and
 
thus activates redox-sensitive as well as 
oxygen-dependent signal
 
transducers. Under hypoxia, in cultured human embryonic 
kidney (HEK) 293 cells and mice, SIRT1 has been shown to selectively stimulate activity 
of the transcription
 
factor HIF-2α during hypoxia and to augment WT HIF-2α-activated 
transcription of isolated mouse vegfA and Epo regulatory regions (Dioum, Chen et al. 
2009).
 
Epo, generally considered an erythropoietic growth factor, is also a potent 
prosurvival factor that protects developing stem cell and progenitor cells in a variety of 
organs (Noguchi, Asavaritikrai et al. 2007). We observed that, in contrast to SIRT1
+/+ 
cells, neither SIRT1
+/- 
nor SIRT1
-/- 
progenitors from aged mice responded to the 
enhancing effects of lowered O2. We might expect that under hypoxia stress, SIRT1
+/- 
and 
SIRT1
-/-
 progenitors still do not respond to lowered O2. We could investigate if SIRT1 
knock-out perturbs the HIF-2α-Epo pathway. Whether HIF-responsive and HIF-2α-
activated transcription of mouse VegfA and Epo regulatory regions respond to SIRT1 
overexpression will be evaluated. Chromatin immunoprecipitation will be performed to 
evaluate whether there is a increase of recruitment of SIRT1and HIF-2α to the Epo 
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enhancer region in hematopoietic stem cells during hypoxia. Pharmacological 
manipulations of SIRT1 activity will be performed. We could expect increased 
abundance of Epo mRNA with agents that stimulate SIRT1 deacetylase activity, and 
decreased Epo mRNA with agents that inhibit SIRT1 deacetylase activity. 
Role of SIRT1 on hematopoiesis 
Vitamin B3 (niacin) is a water-soluble vitamin that occurs in two forms: nicotinamide 
and its acid form, nicotinic acid. Although nicotinamide leads to inhibition of sirtuins, 
both nicotinic acid and nicotinamide lead to increased cellular NAD
+
 production.  
Whether Vitamin B3 treatment directly inhibits sirtuins or, alternatively, upregulates 
these enzymes via increased NAD
+
 production remains to be answered (Denu 2005). 
Skokowa et al. (Skokowa, Lan et al. 2009) reported that G-CSF stimulates nicotinamide 
phosphoribosyltransferase (NAMPT), with subsequent upregulation of NAD
+
 and SIRT1 
synthesis in myeloid progenitors and neutrophils from subjects with congenital 
neutropenia. Notably, treatment of healthy individuals with 10-20 mg kg
-1
 d
-1
 of vitamin 
B3 led to a marked increase in the neutrophilic granulocyte content (up to twofold within 
2 day) in peripheral blood without affecting any other blood cell lineages (Skokowa, Lan 
et al. 2009). G-CSF is the most common mobilizing agent used clinically (Broxmeyer, 
Hangoc et al. 2007; Pelus and Fukuda 2008). The mechanisms of action of G-CSF in 
mobilizing HSCs is complicated and not fully understood. Based of a clinical model, an 
essential role of the nicotinamide-NAMPT-NAD
+
-SIRT1 pathway in G-CSF-triggered 
myelopoiesis has been demonstrated (Skokowa, Lan et al. 2009). Therefore, it will be 
worthwhile to explore further the role of SIRT1 in self-renewal, differentiation, homing 
and engraftment of HSCs, and whether a SIRT1-dependent pathway is involved in G-
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CSF-triggered mobilization. To test this, first we need to determine whether SIRT1 plays 
a role in proliferation, mobilization, homing, or engraftment of HSCs.  
As demonstrated in the Results section, absolute numbers of HPCs were significantly 
decreased by almost half in SIRT1
+/-
 and SIRT1
-/-
 one year old mice. To assess role of 
SIRT1
-/-
 and SIRT1
+/- 
HSC for engraftment and homing. First, we will breed the SIRT1
+/-
 
and SIRT1
-/+
 mice, currently on a mixed strain background, onto a C57BL/6 mouse strain 
background so that the competitive repopulating cells can be assessed in a CD45 
congenic system. Donor cells will be CD45.2, competitor cells will be CD45.1 (Boy J), 
and lethally irradiated recipients will be F1 (Dual CD45.2/CD45.1). This will allow us 
detection of donor, competitor and host cells. Then the repopulating ability will be 
evaluated between SIRT1
+/+
 and SIRT1
-/+
 mice to determine whether SIRT1 plays a role 
in engraftment of HSC. 
We will test whether overexpression of SIRT1, using a lentiviral vector system, enhances 
HPC and HSC growth. Next we will determine the effect of overexpressing SIRT1 on the 
colony-forming ability of hematopoietic cells. Primary mouse BM cells will be 
transduced with SIRT1-lentiviral vectors and GFP
+
 cells will be sorted and then plated in 
semi-solid methycellulose colony assays containing growth factors conducive to 
progenitor cell growth. We will also evaluate whether SIRT1 overexpression enhances 
the survival of primary hematopoietic progenitors in delayed growth factor addition 
colony assays. To determine the effect of SIRT1 overexpression on mouse HSC 
differentiation and self-renewal, we will perform in vivo competitive HSC repopulation 
assays. To further elucidate the effect of SIRT1 overexpression in vivo, the absolute 
numbers of GFP
+
sca-1
+
lineage
-
 cells in transplanted animals at 1, 2 and 4 weeks (short-
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term) after transplantation will also evaluated. Engraftment is a complex process 
involving many physiological processes. The ability of transplanted cells to move from 
PB to the BM shortly after transplantation is called homing and is crucial for establishing 
stable engraftment of donor cells. We will transplant transduced donor cells into 
irradiated recipient mice without competitor cells and analyze the BM of the recipient 
animals 24 hours after transplantation by FACS for chimerism of donor cells. The long-
term engraftment ability of HSCs after overexpression of SIRT1 and multilineage 
differentiation will also be examined and measured. Furthermore, G-CSF-induced HPC 
mobilization will be examined in SIRT1
-/-
 mice to determine whether SIRT1 is involved 
in the migration in the BM. SIRT1
-/-
 mice will be breed onto a C57BL/6 mouse strain. 
Then C57BL/6 SIRT1
+/-
 and the control C57BL/6 mice will be treated with G-CSF. The 
HSC/HPCs in peripheral blood, spleen and bone marrow will be collected, examined by 
in vitro colony assay and compared between C57BL/6 SIRT1
+/-
 and the control C57BL/6 
mice. 
The CD34
+ 
fraction of human umbilical cord blood (hUCB) contains HSCs capable of 
engrafting NOD/SCID mice in vivo. First, the expression of SIRT1 will be evaluated in 
CD34
+ 
fraction. After sorting CD34
+ 
fraction hUCB, cell will be treated with activators 
and inhibitors of SIRT1. The engraftment assay will be performed to evaluate the effect 
of activators and inhibitors of SIRT1 on the engraftment. After 6 weeks, human cell 
engraftment will be assessed by measuring human CD45 positive cells in recipient 
marrow. We would expect treatment of SIRT1 activators resveratrol would enhance 
hUCB CD34
+
 in vivo engraftment of immunodeficient NOD/SCID mice. 
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